BTS/ICS guideline for the ventilatory management of acute hypercapnic respiratory failure in adults

A Craig Davidson,1 Stephen Banham,1 Mark Elliott,2 Daniel Kennedy,3 Colin Gelder,4 Alastair Glossop,5 Alistair Colin Church,6 Ben Creagh-Brown,7 James William Dodd,8,9 Tim Felton,10 Bernard Foëx,11 Leigh Mansfield,12 Lynn McDonnell,13 Robert Parker,14 Caroline Marie Patterson,15 Milind Sovani,16 Lynn Thomas,17 BTS Standards of Care Committee Member, British Thoracic Society/Intensive Care Society Acute Hypercapnic Respiratory Failure Guideline Development Group, On behalf of the British Thoracic Society Standards of Care Committee

SUMMARY OF RECOMMENDATIONS

Principles of mechanical ventilation

Modes of mechanical ventilation

Recommendation
1. Pressure-targeted ventilators are the devices of choice for acute NIV (Grade B).

Good practice points
- Both pressure support (PS) and pressure control modes are effective.
- Only ventilators designed specifically to deliver NIV should be used.

Choice of interface for NIV

Recommendation
2. A full face mask (FFM) should usually be the first type of interface used (Grade D).

Good practice points
- A range of masks and sizes is required and staff involved in delivering NIV need training in and experience of using them.
- NIV circuits must allow adequate clearance of exhaled air through an exhalation valve or an integral exhalation port on the mask.

Indications for and contra-indications to NIV in AHRF

Recommendation
3. The presence of adverse features increase the risk of NIV failure and should prompt consideration of placement in high dependency unit (HDU)/intensive care unit (ICU) (Grade C).

Good practice points
- Adverse features should not, on their own, lead to withholding a trial of NIV.
- The presence of relative contra-indications necessitates a higher level of supervision, consideration of placement in HDU/ICU and an early appraisal of whether to continue NIV or to convert to invasive mechanical ventilation (IMV).

Monitoring during NIV

Good practice points
- Oxygen saturation should be continuously monitored.
- Intermittent measurement of pCO2 and pH is required.

ECG monitoring is advised if the patient has a pulse rate >120 bpm or if there is dysrhythmia or possible cardiomyopathy.

Supplemental oxygen therapy with NIV

Recommendations
4. Oxygen enrichment should be adjusted to achieve SaO2 88–92% in all causes of acute hypercapnic respiratory failure (AHRF) treated by NIV (Grade A).
5. Oxygen should be entrained as close to the patient as possible (Grade C).

Good practice points
- As gas exchange will improve with increased alveolar ventilation, NIV settings should be optimised before increasing the FiO2.
- The flow rate of supplemental oxygen may need to be increased when ventilatory pressure is increased to maintain the same SaO2 target.
- Mask leak and delayed triggering may be caused by oxygen flow rates >4 L/min, which risks promoting or exacerbating patient-ventilator asynchrony. The requirement for high flow rates should prompt a careful check for patient-ventilator asynchrony.
- A ventilator with an integral oxygen blender is recommended if oxygen at 4 L/min fails to maintain SaO2 >88%.

Humidification with NIV

Recommendation
6. Humidification is not routinely required (Grade D).

Good practice point
- Heated humidification should be considered if the patient reports mucosal dryness or if respiratory secretions are thick and tenacious.

Bronchodilator therapy with NIV

Good practice points
- Nebulised drugs should normally be administered during breaks from NIV.
- If the patient is dependent on NIV, bronchodilator drugs can be given via a nebuliser inserted into the ventilator tubing.
Sedation with NIV

**Recommendations**
7. Sedation should only be used with close monitoring (Grade D).
8. Infused sedative/anxiolytic drugs should only be used in an HDU or ICU setting (Grade D).
9. If intubation is not intended should NIV fail, then sedation/anxiolysis is indicated for symptom control in the distressed or agitated patient (Grade D).

**Good practice point**
In the agitated/distressed and/or tachypnoeic individual on NIV intravenous morphine 2.5–5 mg (± benzodiazepine) may provide symptom relief and may improve tolerance of NIV.

**NIV complications**

**Good practice points**
- Minor complications are common but those of a serious nature are rare. Patients should be frequently assessed to identify potential complications of NIV.
- Care is needed to avoid overtightening of masks.
- Previous episodes of ventilator-associated pneumothorax warrant consideration of admission to HDU/ICU and use of NIV at lower than normal inspiratory pressures.
- The development of a pneumothorax usually requires intercostal drainage and review of whether to continue with NIV.

**Sputum retention**

**Recommendations**
10. In patients with neuromuscular disease (NMD), mechanical insufflation and exsufflation should be used, in addition to standard physiotherapy techniques, when cough is ineffective and there is sputum retention (Grade B).
11. Mini-tracheostomy may have a role in aiding secretion clearance in cases of weak cough (NMD/chest wall disease (CWD)) or excessive amounts (COPD, cystic fibrosis (CF)) (Grade D).

**Modes of IMV**

**Recommendations**
12. Spontaneous breathing should be established as soon as possible in all causes of AHRF (Grade C).
13. Controlled IMV may need to be continued in some patients due to severe airflow obstruction, weak muscles leading to poor triggering or to correct chronic hypercapnia (Grade C).

**Good practice point**
In obstructive diseases, controlled IMV should be continued until airway resistance falls.

**Invasive ventilation strategy**

**Recommendations**
14. During controlled ventilation, dynamic hyperinflation should be minimised by prolonging expiratory time (I:E ratio 1:3 or greater) and setting a low frequency (10–15 breaths/min) (Grade C).
15. Permissive hypercapnia (aiming for pH 7.2–7.25) may be required to avoid high airway pressures when airflow obstruction is severe (Grade D).
16. Carbonic anhydrase inhibitors should not be routinely used in AHRF (Grade C).

**Positive end expiratory pressure**

**Recommendation**
17. Applied extrinsic positive end expiratory pressure (ePEEP) should not normally exceed 12 cm (Grade C).

**Sedation in IMV**

**Recommendation**
18. Sedation should be titrated to a specific level of alertness (Grade B).

**Patient-ventilator asynchrony**

**Recommendations**
19. Ventilator asynchrony should be considered in all agitated patients (including NIV) (Grade C).
20. As patients recover from AHRF, ventilator requirements change and ventilator settings should be reviewed regularly (Grade C).

**Use and timing of a tracheostomy**

**Recommendations**
21. Performing routine tracheostomy within 7 days of initiating IMV is not recommended (Grade A).
22. The need for and timing of a tracheostomy should be individualised (Grade D).

**Good practice points**
- In AHRF due to COPD, and in many patients with NMD or obesity hypoventilation syndrome (OHS), NIV supported extubation should be employed in preference to inserting a tracheostomy.
- In AHRF due to NMD, alongside discussion with the patient and carers, the decision to perform tracheostomy should be multidisciplinary and should involve discussion with a home ventilation unit.

**Management of hypercapnic respiratory failure**

**Prevention of AHRF in AECOPD**

**Recommendations**
23. In AHRF due to AECOPD controlled oxygen therapy should be used to achieve target saturations of 88–92% (Grade A).

**Good practice point**
Controlled oxygen therapy should be used to achieve a target saturation of 88–92% in ALL causes of AHRF.

**Role of NIV in AECOPD**

**Recommendations**
24. For most patients with AECOPD, the initial management should be optimal medical therapy and targeting an oxygen saturation of 88–92% (Grade A).
25. NIV should be started when pH<7.35 and pCO2 >6.5 kPa persist or develop despite optimal medical therapy (Grade A).

---

**Table 1 SIGN grades of recommendations**

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>At least one meta-analysis, systematic review, or RCT rated as 1++, and directly applicable to the target population; or A body of evidence consisting principally of studies rated as 1++, directly applicable to the target population and demonstrating overall consistency of results</td>
</tr>
<tr>
<td>B</td>
<td>A body of evidence including studies rated as 2++, directly applicable to the target population and demonstrating overall consistency of results; or Extrapolated evidence from studies rated as 1++ or 1+</td>
</tr>
<tr>
<td>C</td>
<td>A body of evidence including studies rated as 2+, directly applicable to the target population and demonstrating overall consistency of results; or Extrapolated evidence from studies rated as 2+</td>
</tr>
<tr>
<td>D</td>
<td>Evidence level 3 or 4; or Extrapolated evidence from studies rated as 2+</td>
</tr>
</tbody>
</table>

---


on March 27, 2021 by guest. Protected by copyright.
26. Severe acidosis alone does not preclude a trial of NIV in an appropriate area with ready access to staff who can perform safe endotracheal intubation (Grade B).
27. The use of NIV should not delay escalation to IMV when this is more appropriate (Grade C).
28. The practice of NIV should be regularly audited to maintain standards (Grade C).

Starting NIV in COPD

**Good practice points**
- Arterial blood gas (ABG) measurement is needed prior to and following starting NIV.
- Chest radiography is recommended but should not delay initiation of NIV in severe acidosis.
- Reversible causes for respiratory failure should be sought and treated appropriately.
- At the start of treatment, an individualised patient plan (including the patient wherever possible) should document agreed measures to be taken in the event of NIV failure.

Prognostic features relating to use of NIV in COPD

**Recommendations**
29. Advanced age alone should not preclude a trial of NIV (Grade A).
30. Worsening physiological parameters, particularly pH and respiratory rate (RR), indicate the need to change the management strategy. This includes clinical review, change of interface, adjustment of ventilator settings and considering proceeding to endotracheal intubation (Grade A).

**Good practice point**
If sleep-disordered breathing pre-dates AHFR, or evidence of it complicates an episode, the use of a controlled mode of NIV overnight is recommended.

Duration of NIV in COPD

**Recommendation**
31. NIV can be discontinued when there has been normalisation of pH and pCO2 and a general improvement in the patient’s condition (Grade B).

**Good practice points**
- Time on NIV should be maximised in the first 24 h depending on patient tolerance and/or complications.
- NIV use during the day can be tapered in the following 2–3 days, depending on pCO2 self-ventilating, before being discontinued overnight.

Optimising NIV delivery and technical considerations

**Good practice point**
Before considering NIV to have failed, always check that common technical issues have been addressed and ventilator settings are optimal (table 3).

Indications for IMV in AECOPD

**Recommendations**
32. IMV should be considered if there is persistent or deteriorating acidosis despite attempts to optimise delivery of NIV (Grade A).
33. Intubation should be performed in respiratory arrest or peri-arrest unless there is rapid recovery from manual ventilation/provision of NIV (Grade D).
34. Intubation is indicated in management of AHFR when it is impossible to fit/use a non-invasive interface, for example, severe facial deformity, fixed upper airway obstruction, facial burns (Grade D).
35. Intubation is indicated where risk/benefit analysis by an experienced clinician favours a better outcome with IMV than with NIV (Grade D).

Outcome following NIV or IMV in AECOPD

**Recommendations**
36. Prognostic tools may be helpful to inform discussion regarding prognosis and with regard to the appropriateness of IMV but with the caveat that such tools are poorly predictive for individual patient use (Grade B).
37. Clinicians should be aware that they are likely to underestimate survival in AECOPD treated by IMV (Grade B).
38. Clinicians should discuss management of possible future episodes of AHFR with patients, following an episode requiring ventilatory support, because there is a high risk of recurrence (Grade B).

Acute asthma

**Recommendations**
39. NIV should not be used in patients with acute asthma exacerbations and AHFR (Grade C).
40. Acute (or acute on chronic) episodes of hypercapnia may complicate chronic asthma. This condition closely resembles COPD and should be managed as such (Grade D).

Non-CF bronchiectasis

**Recommendations**
41. In patients with non-CF bronchiectasis and AHFR, controlled oxygen therapy should be used. (Grade D)
42. In patients with non-CF bronchiectasis, NIV should be started in AHFR using the same criteria as in AECOPD (Grade B).
43. In patients with non-CF bronchiectasis, NIV should usually be tried before resorting to IMV in those with less severe physiological disturbance (Grade C).
44. In non-CF bronchiectasis, the patient’s clinical condition prior to the episode of AHFR, and the reason for the acute deterioration, should be evaluated and used to inform the decision about providing IMV (Grade C).

**Good practice points**
- In patients with non-CF bronchiectasis, the precipitating cause is important in determining short-term prognosis.
- Health status prior to the episode of AHFR is an important predictor of outcome.

Cystic fibrosis

**Recommendations**
45. In patients with CF, controlled oxygen therapy should be used in AHFR (Grade D).
46. In patients with CF, NIV is the treatment of choice when ventilatory support is needed (Grade C).
47. In patients with CF, specialised physiotherapy is needed to aid sputum clearance (Grade D).
48. In patients with CF, a mini-tracheostomy combined with NIV may offer greater chance of survival than resorting to IMV (Grade D).

Restrictive lung diseases

**NMD and CWD**

**Recommendations**
49. Controlled oxygen therapy should be used in patients with NMD or CWD and AHFR (Grade D).
In patients with NMD or CWD, nocturnal NIV should be anticipated that bulbar dysfunction and communication difficulties, if present, will make NIV delivery difficult, and may make it impossible. Discussion about NIV and IMV, and patients’ wishes with respect to cardiopulmonary resuscitation, should occur as part of routine care of patients with NMD or CWD.

In patients with NMD or CWD, intolerance of the mask and/or rapid desaturation during a break from NIV are important warning signs. In patients with NMD or CWD, the presence of bulbar dysfunction makes NIV failure more likely. Deterioration in patients with NMD or CWD may be very sudden. Difficulty achieving adequate oxygenation or rapid desaturation during a break from NIV are important warning signs. In patients with NMD or CWD, the presence of bulbar dysfunction, more profound hypoxaemia or rapid desaturation during NIV breaks, suggests that placement in HDU/ICU is indicated.

PEEP in the range of 5–10 is commonly required to increase residual volume and reduce oxygen dependency in both patient groups.

Obesity hyperventilation syndrome

56. Controlled oxygen therapy should be used in patients with OHS and AHRF (Grade D).
57. In patients with OHS, NIV should be started in AHRF using the same criteria as in AECOPD (Grade B).
58. NIV is indicated in some hospitalised obese hypercapnic patients with daytime somnolence, sleep disordered breathing and/or right heart failure in the absence of acidosis (Grade D).

NIV settings and placement in OHS

Good practice points

- High inspiratory positive airway pressure (IPAP) and expiratory positive airway pressure (EPAP) settings are commonly required in patients with OHS (eg, IPAP > 30, EPAP > 8).
- Volume control (or volume assured) modes of providing NIV may be more effective when high inflation pressures are required.

NIV failure in OHS

Good practice points

- Fluid overload commonly contributes to ventilatory failure in patients with OHS, and its degree is easily underestimated.
- Forced diuresis may be useful.
- As the risk of NIV failure is greater, and intubation may be more difficult, placement in HDU/ICU for NIV is recommended.

Discontinuing NIV in OHS

Good practice points

- NIV can be discontinued, as in patients with AECOPD.
- Many patients with AHRF secondary to OHS will require long-term domiciliary support (CPAP or NIV).
- Following an episode of AHRF referral to a home ventilation service is recommended.

IMV strategy in OHS

Good practice points

- In patients with OHS, pressure controlled MV is recommended initially.
- In patients with OHS, high PEEP settings may be needed to recruit collapsed lung units and correct hypoxaemia.
- In patients with OHS, a forced diuresis is often indicated.

Weaning from IMV

Introduction

Recommendations

59. Treating the precipitant cause of AHRF, normalising pH, correcting chronic hypercapnia and addressing fluid overload should all occur before weaning is started (Grade D).
60. A brain natriuretic peptide (BNP)-directed fluid management strategy should be considered in patients with known left ventricular dysfunction. (Grade B)

Weaning methods

Recommendations

61. Assessment of the readiness for weaning should be undertaken daily (Grade C).
62. A switch from controlled to assisted IMV should be made as soon as patient recovery allows (Grade C).
63. IMV patients should have a documented weaning plan (Grade B).

Assessing readiness for discontinuation of mechanical ventilation

Recommendation

64. A 30 min spontaneous breathing trial (SBT) should be used to assess suitability for extubation (Grade B).

65. Factors including upper airway patency, bulbar function, sputum load and cough effectiveness should be considered prior to attempted extubation (Grade D).

Outcome following extubation

Recommendation

66. Care is needed to identify factors that increase the risk of extubation failure so that additional support, such as NIV or cough assist, can be provided (Grade B).

Weaning protocols

Recommendations

67. Although an organised and systematic approach to weaning is desirable, protocols should be used with caution in patients with AHRF (Grade B).

68. The use of computerised weaning cannot be recommended in AHRF (Grade D).

Use of NIV in the ICU

Planned NIV to speed weaning from IMV

Recommendation

69. NIV is recommended to aid weaning from IMV in patients with AHRF secondary to COPD (Grade B).

70. In other causes of AHRF, NIV may have a role in shortening the duration of IMV when local expertise in its use exists (and of cough assist when indicated) and there are features present that indicate extubation is likely to be successful (Grade D).

NIV in high-risk patients

Recommendation

71. Prophylactic use of NIV should be considered to provide post-extubation support in patients with identified risk factors for extubation failure (Grade B).

NIV as ‘rescue’ therapy post-extubation

Recommendations

72. NIV should not be used routinely for unexpected post-extubation respiratory failure (Grade B).

73. In COPD, a trial of NIV may be justified for unexpected post-extubation respiratory failure where local expertise exists (Grade D).

Care planning and delivery of care

Appropriate care environments for the delivery of NIV

Recommendations

74. NIV services should operate under a single clinical lead having formal working links with the ICU (Grade D).

75. The severity of AHRF, and evidence of other organ dysfunction, should influence the choice of care environment (Grade C).

76. NIV should take place in a clinical environment with enhanced nursing and monitoring facilities that are beyond those of a general medical ward (Grade C).

77. Initial care plans should include robust arrangements for escalation, anticipating that around 20% of AHRF cases should be managed in a level 2 or 3 environment (Grade C).

Good practice points

- A 2–4 bedded designated NIV unit (located within a medical high dependency area or within a respiratory ward with enhanced staffing levels) provides a sound basis for the provision of NIV in a DGH serving a population of 250 000 and with an average prevalence of COPD.

- Areas providing NIV should have a process for audit and interdisciplinary communication.

Palliative care and advanced care planning

Recommendations

78. Clinicians delivering NIV or IMV should have ready access to palliative medicine (Grade D).

79. Multidisciplinary advance care planning should be an integral part of the routine outpatient management of progressive or advanced disease and care plans should be reviewed on presentation during an episode of AHRF (Grade D).

80. The use of NIV may allow time to establish patient preference with regard to escalation to IMV (Grade D).

End of life care

Good practice points

- Although removal of the NIV mask may be agreed as preferable, a dignified and comfortable death is possible with it in place.

- Clinicians delivering NIV or IMV should have training in end-of-life care and the support of palliative care teams.

Novel therapies

Extracorporeal CO₂ removal (ECCO₂R)

Recommendations

81. If local expertise exists, ECCO₂R might be considered:

- If, despite attempts to optimise IMV using lung protective strategies, severe hypercapnic acidosis (pH<7.15) persists (Grade D);

- When ‘lung protective ventilation’ is needed but hypercapnia is contraindicated, for example, in patients with coexistent brain injury (Grade D);

- For IMV patients awaiting a lung transplant (Grade D).

Good practice point

ECCO₂R is an experimental therapy and should only be used by specialist intensive care teams trained in its use, and where additional governance arrangements are in place, or in the setting of a research trial.

Helium/oxygen ventilation

Recommendation

82. Heliox should not be used routinely in the management of AHRF (Grade B).

ABBREVIATIONS AND GLOSSARY

- ABG: Arterial blood gases
- AECOPD: Acute exacerbation of COPD
- AHRF: Acute hypercapnic respiratory failure
- APACHE II: Acute Physiology and Chronic Health Evaluation: a severity of illness score
- ARDS: Acute Respiratory Distress Syndrome
- Bi-level/Bi-PAP: Ventilation mode using 2 levels of pressure support
- BMI: Body mass index
- BODE: Body mass index, obstruction, dyspnoea and exercise tolerance score
- Bpm: Heart rate (beats per minute)
- BTS: British Thoracic Society
**INTRODUCTION**

**Background**

The British Thoracic Society (BTS) published the guideline, ‘The use of non-invasive ventilation in acute respiratory failure’, in 2002. This was in response to trials demonstrating that NIV was an alternative to IMV in life-threatening respiratory acidosis due to AECOPD. The guideline drew attention to evidence that, when NIV was used in the less severely unwell patient, it also limited progression to more severe respiratory failure. The trial also demonstrated the feasibility, with adequate staff training, of delivering NIV on a general medical or admission ward with enhanced support.

In subsequent years, NIV has been shown to deliver better rather than equivalent outcomes to invasive ventilation in AECOPD (see Management of hypercapnic respiratory failure section). Although the 2002 guideline recognised NIV to be effective in other causes of AHRF, the evidence was, based largely on an extrapolation from its domiciliary use in neuromuscular and CWD. In the intervening years, better evidence has accumulated for the use of NIV in non-COPD disease. Repeated national audits have, however, raised concerns that expected patient benefit is not being delivered, and have pointed to a number of process deficiencies. There is also the risk, in the absence of justifying trial evidence, that the preferred use of NIV in AECOPD might be extended to all hypercapnic patients, irrespective of circumstance or underlying disease process. That this is a real risk might be inferred from the BTS audits where the indication for NIV was not COPD in over 30% of cases.

NIV development in the UK has been largely outside the organisational ‘umbrella’ of critical care. This may have adversely affected resource allocation and contributed to a lack of integration in NIV and IMV patient pathways. Other unintended consequences might be a restriction on access to invasive ventilation and delay in the development of extended applications of NIV, such as accelerating extubation and its use in the management of post-extubation respiratory failure, in ICUs. The ‘closed unit’ approach advocated in critical care may also have made care of the invasively ventilated respiratory patient the preserve of the intensivist. Such specialists may have little experience of the ability of domiciliary NIV to reverse chronic cardiorespiratory failure and this may lead to underestimating survival, particularly in advanced NMD or CWD.

For these varied reasons, the need for up-to-date guidance was acknowledged by BTS and the Intensive Care Society (ICS). The aim of the guideline is to draw attention to the evidence of suboptimal care in AHRF in the UK, provide an overview of the evidence supporting the use of invasive and non-invasive ventilation, encourage better communication between admitting clinicians and critical care services, promote the use of AHRF patient pathways, and improve resourcing, training, outcomes and patient experience for all adults who develop AHRF.

**Definition of AHRF**

AHRF results from an inability of the respiratory pump, in concert with the lungs, to provide sufficient alveolar ventilation to maintain a normal arterial PCO₂. Co-existent hypoxaemia is usually mild and easily corrected. Conventionally, a pH <7.35 and a PCO₂ >6.5 kPa define acute respiratory acidosis and, when persisting after initial medical therapy, have been used as threshold values for considering the use of non-invasive ventilation. More severe degrees of acidosis, such as pH <7.25, have been used as a threshold for considering provision of IMV.

**Importance of AHRF**

AHRF complicates around 20% of acute exacerbations of COPD. It signals advanced disease, a high risk of future hospitalisations and limited long-term prognosis. The median survival following recovery from AHRF was 1 year in a large case series. Around 12% of patients with hypercapnic COPD died during the index admission and this increased to 33% if the respiratory acidosis developed after hospitalisation. In asthma, acute hypercapnia also signals an increased risk of death and an
introduced likelihood of future life-threatening attacks. The same risks apply to AHRF complicating CF and bronchiectasis, although this has not been formally reported. In the neuromuscular and CWDs, including morbid obesity, respiratory pump failure is often insidious in its onset, but AHRF may be acute and unexpected. Acute on chronic ‘decompensated’ episodes of AHRF are more common and normally indicate the future need for domiciliary NIV.

Intended use and target audience of the guideline

A central theme of the guideline is to promote integration in the planning and delivery of NIV and IMV in AHRF. Despite evidence demonstrating the value of non-invasive ventilation in the management of AHRF, its introduction into routine clinical practice in the UK has not delivered the expected patient benefit and it is likely that NIV provision has, inadvertently, reduced access to IMV in AECOPD and the other causes of AHRF. The introduction, in hospitals accepting acute admissions, of an adequately resourced and integrated AHRF patient pathway is strongly recommended in the expectation that this will lead to improved clinical outcomes and patient experiences.

The target audience for the guideline is medical, nursing and physiotherapy staff working in emergency receiving rooms, medical assessment units, admission wards, respiratory wards and in high dependency and critical care units. The guideline applies to adults. For information on NIV in children with neuromuscular weakness, see the BTS guideline Respiratory Management of Children with Neuromuscular Weakness.

Areas not covered by the guideline

The guideline does not cover the management of AHRF due to cardiac failure, trauma or acute brain injury. The guideline refers to domiciliary NIV but does not aim to provide guidance on this. The use of non-invasive ventilation is more extensively covered than IMV because the evidence and the clinical experience in its use is recent and because the technical aspects concerning IMV are well covered by standard texts.

Units

Intrathoracic pressure and pressures relating to mechanical ventilation are presented as cm H₂O. ABG tensions are presented as kPa.

Guideline group members

A list of Guideline Group members and BTS Standards of Care Committee members who assisted with the production of the guideline is given in appendix 1. The Guideline Group members adhered to the BTS and ICS policies for the Declaration of Interests and, where appropriate, specific relevant interests are declared in appendix 1.

Methods and terminology

The guideline has been produced according to the BTS Guideline Production manual and adheres to the criteria set out in the AGREE II instrument.

Clinical questions and literature search

Clinical questions were gathered in the PICOT (Patient, Intervention, Comparison, Outcome and Time) format to define the scope of the guideline and inform the literature search. Systematic electronic database searches were conducted in order to identify potentially relevant studies for inclusion in the guideline. For each clinical question, the following databases were searched: Ovid MEDLINE (including MEDLINE In-Process), Ovid EMBASE, EMSCO CINAHL, Ovid PsycINFO and the Cochrane Library (including the Cochrane Database of Systematic Reviews, the Database of Abstracts of Reviews of Effects and the Cochrane Central Register of Controlled Trials).

An initial search was carried out in November 2010, using a combination of indexed and free text terms defining the clinical questions that had been agreed as important in formulating guidelines in AHRF. It was limited to studies after 1990, on adults, in journals published in English and where at least an abstract was available. The searches identified a total of 582 potential papers, which were subsequently supplemented by publications known to members or resulting from additional searches undertaken by the writing groups after 2010. The literature search was run again in September 2013, for relevant publications between 2010 and 2013, yielding a further 308 potentially relevant references. Additional references were subsequently included from personal collections.

Appraisal of the literature

Appraisal was performed using the criteria stipulated by the AGREE collaboration. Each paper was appraised by at least two reviewers. The writing lead for each section read the title and abstract of papers identified and agreed with at least one member of each writing group on whether such a paper was definitely relevant, possibly relevant or not relevant to the section. The criteria used were that the paper addressed a clinical question, the study method used was satisfactory and that the paper was available in English.

Full papers were obtained for all relevant or possibly relevant abstracts. Two members for each section independently appraised each paper, using the SIGN critical appraisal checklists. An evidence level was assigned to each study using SIGN methodology (table 2). These evidence levels are shown in the evidence tables presented in the online supplementary appendix 3.

Considered judgement and grading of recommendations

The guideline group used the evidence tables to judge the body of evidence and to develop recommendations for this guideline. Where evidence was lacking, expert opinions were obtained by consensus. The following were considered in the grading of the recommendations: the number of studies and number of patients providing evidence, the applicability of such evidence, and whether generalisable to the patient groups in the guideline and to UK practice and the degree of strength as judged by the consistency of evidence obtained to support recommendations.

<table>
<thead>
<tr>
<th>Evidence Level</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>++</td>
<td>High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias</td>
</tr>
<tr>
<td>+</td>
<td>Well-conducted meta-analyses, systematic reviews or RCTs with a low risk of bias</td>
</tr>
<tr>
<td>−</td>
<td>Meta-analyses, systematic reviews or RCTs with a high risk of bias</td>
</tr>
<tr>
<td>++</td>
<td>High-quality systematic reviews of case control or cohort or studies, high-quality case-control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal</td>
</tr>
<tr>
<td>+</td>
<td>Well-conducted case-control or cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal</td>
</tr>
<tr>
<td>−</td>
<td>Case-control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal</td>
</tr>
<tr>
<td>0</td>
<td>Non-analytic studies, eg, case reports, case series</td>
</tr>
<tr>
<td>4</td>
<td>Expert opinion</td>
</tr>
</tbody>
</table>

RCT, randomised controlled trial.
Recommendations were graded from A to D, using the SIGN Grading System (table 2), as indicated by the strength of the evidence as listed in the tables. Important practical points that lack research evidence were highlighted as ‘Good Practice Points’.  

**Good practice points**

Recommended best practice based on the clinical experience of the guideline development group.

**Drafting the guideline**

The Guideline Group corresponded regularly. The initial meeting took place in October 2009, and subsequent meetings of the full committee occurred in June and November 2010, September 2011, and March and September 2012. Draft documents were reviewed by the BTS Standards of Care Committee at meetings in 2013 and 2014, and a final draft was produced with the help and collaboration of members of the BTS Standards of Care Committee in September 2014 to March 2015. The guideline was made available for public consultation on the BTS website from 7 May to 12 June 2015. The revised document was reviewed by the BTS Standards of Care Committee in September 2015 and final approval for publication was given in November 2015.

**PRINCIPLES OF MECHANICAL VENTILATION**

**Modes of mechanical ventilation**

There are two basic modes of providing mechanical ventilation. In volume-targeted, the operator sets the tidal volume to be delivered and the duration of inspiration (Ti). The ventilator generates whatever pressure is necessary to deliver this volume within this time. In pressure-targeted, the operator sets the inspiratory pressure. The volume of air the patient receives is a function of the impedance to inflation of the lungs and chest wall and the inspiratory time. The Ti should be of sufficient length to achieve an adequate volume and at a frequency that allows the patient time to fully exhale.

The terminology used for pressure-targeted ventilation can cause confusion. In bi-level ventilation, one pressure is set for inspiration (IPAP) and a second pressure for expiration (EPAP). The difference between the two is the level of ventilatory assistance or PS. This mode is most commonly used for NIV. The same term, CPAP with Pressure Support’, can be used to describe a mode of invasive ventilation and/or non-invasive ventilation on some ICU ventilators. The operator sets an incremental inspiratory pressure above the CPAP setting rather than setting an absolute level of inspiratory pressure.

Pressure-targeted ventilation has a number of advantages. First, the pressure delivered is constant and this avoids the tendency for upper airway collapse during expiration.

In spontaneous and pressure-targeted delivery, the patient must generate a sufficient inspiratory pressure by triggering the ventilator. The lower the trigger sensitivity, the greater effort the patient needs to make to trigger a supported breath. Different trigger settings may be required for individual causes of AHRF (see Management of hypercapnic respiratory failure section).

S/T is the NIV mode most commonly employed in treating AHRF. There have been no trials comparing PS ventilation and PCV in the treatment of AHRF. Bench studies suggest that ventilators designed specifically for NIV have superior performance over standard ICU ventilators used to deliver NIV, particularly in the presence of significant leak. The extent to which individual types of ICU ventilators (set in the NIV mode) can compensate for leak and the adequacy of patient triggering varies. Generally, ICU ventilators appear more prone to patient-ventilator asynchrony than home care ventilators.

**Evidence statement**

Most RCTs that demonstrate an advantage to NIV in AHRF have used pressure targeted ventilators (Level 1+).

**Recommendation**

1. Pressure targeted ventilators are the devices of choice for acute NIV (Grade B).

**Good practice points**

- Both PS and pressure control modes are effective.
- Only ventilators designed specifically to deliver NIV should be used.

**Choice of interface for NIV**

The FFM is the most suitable interface, as mouth breathing predominates in AHRF. To accommodate the natural diversity of the human face, a range of shapes and sizes of FFM should be available. Reported studies suggest that different types of interfaces do not affect outcome, but the trials have been small and comparison of masks has been inadequately powered to detect a difference. The helmet interface, which covers the whole head, is an alternative to an FFM, but triggering is ineffective. Patients may report about noise caused by turbulence within the helmet, and it is not possible to provide humidified gases because of ‘rain out’ in the helmet. A mask that covers the whole of the face (including the eyes, but not the ears) is useful when air leak remains excessive or when nasal bridge ulceration develops, and is sometimes better tolerated by the confused or agitated patient. In those who find the FFM claustrophobic or distressing, experienced practitioners may consider using a nasal mask or nasal pillows. Mouth leak limits the effectiveness of nasal interfaces during sleep and nasal pillows are more easily dislodged than the FFM.

Ventilators designed for NIV usually employ a single lumen circuit whereas IMV ventilators use a dual lumen circuit (separate tubing for inhalation and exhalation). In the former, a mask with an integral exhalation port is commonly used. If not, an exhalation port needs to be inserted into the ventilator circuit close to the mask. A minimum EPAP of 3 cm is required to vent inspiratory effort. ‘Pressure-controlled ventilation’ (PCV) is the term used to describe a mode in which the operator sets the inspiratory pressure, the length of inspiration and the inspiratory rate. In the spontaneous/timed (S/T) mode (also known as assist control), a backup rate is set by the operator. If the patient’s RR is slower than the backup rate, machine-determined breaths will be delivered (ie, controlled ventilation). If the patient breathes faster than the backup rate, no machine determined breaths will be delivered and all breaths will be triggered (or assisted). The proportion of controlled and assisted breaths often varies, depending on the patient’s state of alertness and respiratory drive.

Trigger sensitivity refers to the effort required by the patient to initiate, or trigger, the ventilator. The lower the trigger sensitivity, the greater effort the patient needs to make to trigger a supported breath. Different trigger settings may be required for individual causes of AHRF (see Management of hypercapnic respiratory failure section).
exhaled air. The website http://ersbuyersguide.org/ offers information on NIV interfaces that are currently available.

**Evidence statement**

An FFM is the interface of choice for general/non-specialist use (Level 4).

**Recommendation**

2. An FFM should usually be the first type of interface used (Grade D).

**Good practice points**

- A range of masks and sizes is required, and staff involved in delivering NIV need training in and experience of using them.
- NIV circuits must allow adequate clearance of exhaled air through an exhalation valve or an integral exhalation port on the mask.

**Indications for and contra-indications to NIV in AHRF**

The indication for NIV will vary according to the underlying cause, severity of illness and associated complicating factors. Broad criteria can be used and are summarised in figure 1, and further discussed in Management of hypercapnic respiratory failure section. Severe facial deformity, fixed upper airway obstruction or facial burns, will occasionally make NIV impossible. A number of other contra-indications have been suggested (see figure 1). These have most often been employed as exclusion criteria in clinical trials rather than being definitively shown to result in a worse outcome. Some of the criteria have been challenged. For instance, coma has been regarded as an absolute contra-indication, because of its associated loss of airway protection, but Diaz et al report similar outcomes with NIV in those with a Glasgow Coma Score <8 as the outcomes found in more alert patients. Similarly, confusion, agitation and cognitive impairment make NIV more difficult to apply but should not preclude its use.

There is less haemodynamic compromise with NIV than with IMV, and hypotension should rarely preclude using NIV. Significant arrhythmia, especially if causing hypotension, may tip the balance towards preferring intubation as, in these circumstances, cardioversion may be indicated.

An acute pneumothorax should be drained before applying NIV. If it is too small to allow the safe placement of a chest drain (or is suspected to be chronic) NIV may proceed with careful monitoring. Using a lower inflation pressure seems theoretically sensible but is without evidence. If the patient deteriorates, NIV should be discontinued—in case it is contributing to the development of a tension pneumothorax—and an urgent chest radiograph obtained.

Vomiting has been considered a contra-indication. The key issue is whether the NIV mask can be rapidly removed, that is, an assessment of whether the patient can signal the need to vomit. Marked abdominal distension may sometimes precipitate AHRF in individuals at risk, for example in COPD or morbid obesity. Management should then address the underlying cause of abdominal distension and manage the risk of vomiting by inserting a nasogastric tube. Similarly, in the at-risk patient, hypercapnic respiratory failure may complicate the later stages of pregnancy (e.g., kyphoscoliosis or muscular dystrophy). NIV is ideally suited to manage this complication. The need for NIV should be electively assessed (by nocturnal monitoring), but mask ventilation can be initiated during delivery should respiratory distress develop in an at-risk patient.

The presence of copious secretions increases the risk of treatment failure, but NIV may also improve the ability to clear secretions and improve alveolar ventilation.

**Figure 1**

*Summary for providing acute non-invasive ventilation.*

**Indications for NIV**

- **COPD**
  - $pH < 7.35$
  - $PCO_2 > 65$
  - RR > 30 or usual VC < 11 even if $PCO_2 > 65$
  - Or $pH < 7.35$ and $PCO_2 > 65$

- **Neuromuscular disease**
  - Respiratory failure with $RR > 20$ or usual VC < 11 even if $PCO_2 > 65$
  - Daytime $PCO_2 > 6.5$

- **Obesity**
  - $pH < 7.35$, $PCO_2 > 45$, RR > 20
  - Daytime $PCO_2 > 6.5$, and somnolent

**Contraindications for NIV**

- **Absolute**
  - Severe facial deformity
  - Fixed upper airway obstruction
  - Fixed airway obstruction
  - Indications for referral to ICU
    - Afflict with impending respiratory arrest
    - Inability to maintain $SpO_2 > 88$ on NIV
    - Need for IV sedation or adverse features indicating need for close monitoring and/or possible difficult intubation asin OHH, CMO.

**NIV SETUP**

- **Mask**
  - Full face mask (or own if home user of NIV)

- **Initial Pressure settings**
  - EPAP: 3 (or higher if OSA known/expected)
  - IPAP in COPD/mixed 15 (20 if $pH < 7.25$)
  - Uprate IPAP over 10–30 mins to IPAP 20–30 to achieve adequate augmentation of chest/sternal movement and slow RR

- **Backup rate**
  - Backup rate of 16-20. Set appropriate inspiratory time

- **I:E ratio**
  - COPD 1.2 to 1.3
  - OHH, N&O C:O 1:1

- **Inspiratory time**
  - O&N 1.2 to COPD
  - 1.2:1.5 to OHH, N&O

**NIV Monitoring**

- **Oxygenation**
  - Arterial BB-Oct in all patients
  - Note: Home style ventilators CANNOT provide 50% inspired oxygen.

- **Red flags**
  - $pH < 7.5$ on optimal NIV
  - RR persisting > 25
  - New onset confusion or patient distress

- **Actions**
  - Check sedation/intubation, pad M&L, exhalation port
  - Give physiotherapy/bronchodilators, consider intubation

**CONSIDER IMV**

*Possible need for EPAP > 8*

- Severe OHH (BMI > 35), lung recruitment during hypoxia in severe kyphoscoliosis, opiate/narcotic PEEP in severe soft tissue obstruction or to maintain adequate PS when high EPAP required.
Respiratory arrest or peri-arrest have been considered as absolute contra-indications as NIV is intended to supplement spontaneous breathing. However, as bag and mask ventilation (itself a form of NIV) is used as a prelude to intubation, a short trial of NIV by an experienced operator, can be justified while paying special attention to the risk of glottic occlusion. In summary, the presence of adverse features is an indication for more intense monitoring and placement within HDU/ICU rather than a contra-indication per se.

**Evidence statement**

There are few absolute contra-indications to a trial of NIV but some adverse features, especially when combined, require more caution and more intense monitoring (Level 4).

**Recommendation**

3. The presence of adverse features increases the risk of NIV failure (Level 2++).

**Good practice points**

- Adverse features should not, on their own, lead to withholding a trial of NIV.
- The presence of relative contra-indications necessitates a higher level of supervision, consideration of placement in HDU/ICU and an early appraisal of whether to continue NIV or to convert to IMV.

**Monitoring during NIV**

Continuous monitoring of oxygen saturation is essential. Repeated measurement of ABG tensions will be required and can be assessed by capillary sampling or intermittent arterial puncture, noting that capillary sampling is less painful for the patient. One advantage of HDU/ICU placement may be to allow the safe use of an indwelling arterial line for blood sampling. Transcutaneous pCO₂ (TcPO₂) monitoring is a commonly employed investigation in home ventilation units and the devices are increasingly being employed in hospitals. Small studies have reported on its use in acute respiratory acidosis. A study by van Oppen et al reported on 10 patients receiving acute NIV and demonstrated that TcPO₂ monitoring is reliable over 12h and provides an adequate estimate of pH. Further studies are needed to assess the role of transcutaneous CO₂ monitoring.

ECG monitoring is advised for all patients with a tachycardia >120 bpm, dysrhythmia or known cardiomyopathy. As in all severely ill patients, serial vital signs (and National Early Warning Scores, where implemented) should be recorded.

**Good practice points**

- Oxygen saturation should be continuously monitored.
- Intermittent measurement of pCO₂ and pH is required.
- ECG monitoring is advised if the patient has a pulse rate >120 bpm or if there is dysrhythmia or possible cardiomyopathy.

**Supplemental oxygen therapy with NIV**

There are no trials to guide the use of oxygen enrichment. It is well recognised that hyperoxygenation is harmful in the self-ventilating patient with AHFR. In the absence of harm from modest hypoxaemia, and to avoid confusion that might arise from having different target saturations in different conditions, a saturation range of 88–92% is recommended in all patients with AHFR either spontaneously breathing or when receiving NIV. This is usually easily achieved in AECOPD, but severe hypoxaemia may complicate AHFR in other causative diseases such as CWD.

As for the best method of supplying oxygen, Padkin and Kinnear, in a study of patients who were not acutely unwell, reported no difference in inspired content whether delivered directly into the NIV mask or into the ventilator tubing close to the mask. Introducing oxygen at the ventilator end of the tubing was less effective. The mean FiO₂ achieved was 31% at 1 L/min, 37% at 2 L/min, 40% at 3 L/min and 44% at 4 L/min. Flow rates >4 L/min provided minimal additional increase. Kaul found that the higher the inspiratory pressure, the less additional benefit resulted from higher flow rates (because higher pressures increase leak). High flow rates also resulted in delayed triggering the ventilator. As this risks promoting patient ventilator asynchrony, technically advanced NIV ventilators that allow precise oxygen blending (and a higher FiO₂ enrichment) are a safer and more appropriate alternative when hypoxaemia is severe.

**Evidence statements**

In AHFR-targeted oxygen therapy (SaO₂ 88–92%) reduces mortality (Level 1+). When providing NIV, oxygen enrichment is best given at or near the mask (Level 3).

**Recommendations**

4. Oxygen enrichment should be adjusted to achieve SaO₂ 88–92% in all causes of AHFR being treated by NIV (Grade A).

5. Oxygen should be entrained as close to the patient as possible (Grade C).

**Good practice points**

- As gas exchange will improve with increased alveolar ventilation, NIV settings should be optimised before increasing the FiO₂.
- The flow rate of supplemental oxygen may need to be increased when ventilatory pressure is increased to maintain the same SaO₂ target.
- Mask leak and delayed triggering may be caused by oxygen flow rates >4 L/min, which risks promoting or exacerbating patient–ventilator asynchrony. The requirement for high flow rates should prompt a careful check for patient–ventilator asynchrony.
- A ventilator with an integral oxygen blender is recommended if oxygen at 4 L/min fails to maintain SpO₂ >88%.

**Humidification with NIV**

There is no evidence to guide the use of humidification in acute NIV. Heated humidification may reduce upper airway resistance and increase comfort when leak is high. In short-term studies, heated humidification reduces upper airway dryness, which might improve tolerance and aid secretion clearance, but this has not been proven. Humidification should only be considered when upper airway dryness is a problem or secretions are difficult to expectorate.

**Evidence statement**

No evidence exists to guide humidification practice in acute NIV (Level 4).

**Recommendation**

6. Humidification is not routinely required (Grade D).

**Good practice point**

Heated humidification should be considered if the patient reports mucosal dryness or if respiratory secretions are thick and tenacious.
Bronchodilator therapy with NIV
As part of a PhD thesis, Kaul found that nebulised bronchodilators given concomitantly with NIV in stable patients produced less benefit than when given while patients were breathing spontaneously. Brief discontinuation of NIV for the administration of bronchodilators appears to be safe. Accordingly, bronchodilator therapy is probably better given during breaks in NIV. This may also facilitate coughing and the clearing of respiratory secretions. If discontinuing NIV results in patient distress, it should be continued and a nebuliser sited proximally in the circuit.

Good practice points
- Nebulised drugs should normally be administered during breaks from NIV
- If the patient is dependent on NIV, bronchodilator drugs can be given via a nebuliser inserted into the ventilator tubing.

Sedation with NIV
Patient agitation and distress are common in AHRF and may be made worse by the application of NIV before gas exchange has improved and the patient has sensed a reduction in the work of breathing. Despite this, sedatives/anxiolytics and/or opiates are infrequently used due to concern about depressing respiratory drive. This is understandable if NIV is delivered in an inappropriate environment that is unable to provide continuous monitoring and that does not have the ready availability of medical staff to perform safe intubation if needed. On the contrary, relieving patient distress is an important goal and might be expected to increase comfort and the success of NIV. In a 2007 survey of members of the critical care assemblies of the American College of Chest Physicians and the European Respiratory Society, respondents reported using sedatives or opiates in only 25% of cases and 21% stated they had never used either.

The risk of respiratory depression was given as the reason for non-use. Individual practice was highly variable and, as the response rate was poor (42% European, 14% North American), the conclusions reported are more qualitative than quantitative. When treatment was given it was mostly by bolus injection and rarely according to a sedation protocol. Greater experience in the use of NIV and being a critical care clinician increased reported use of opiates/sedation.

In the 2013 BTS audit, involving 2693 cases, NIV failed to reverse AHRF in 30% of patients. Agitation was reported as the principal reason in 31% of these. Sedation was ‘attempted’ in 84%. No details are available on what agents were used, or outcome in those so treated. As 91% of all NIV treatments were provided outside of the HDU/ICU, it appears sedation is now more commonly employed but in a potentially unsafe environment.

In the ICU setting, case series have reported that infusions of propofol, dexmedetomidine and remifentanil are safe, improve comfort and reduce the failure rate of NIV. Senoglu et al. compared infusions of dexmedetomidine and midazolam in 45 AECOPD cases with AHRF, using a protocol aiming at a standard degree of sedation. No differences were found in effectiveness between the two agents. There were no significant adverse events and no patient failed to improve with NIV. In another report, the addition of infused dexmedetomidine to a standard protocol of ‘as needed’ bolus intravenous midazolam and fentanyl, given according to a sedation protocol, failed to show benefit, but sedation goals were readiness achieved and there was good NIV tolerance and success with the standard protocol. A review of sedation to facilitate NIV tolerance makes the pharmacological case for preferring an opiate to a benzodiazepine (because the latter promotes upper airway obstruction through inhibiting the pharangeal dilating muscles) but concluded that studies to date have been too small, have used different drugs and therapy regimes and employed a variety of outcome measures.

Guidance on the use of sedation within hospitals might be expected to improve patient safety when implemented.

Evidence statements
Patient distress is common in AHRF and often made initially worse by applying NIV (Level 4).
There is inadequate evidence to guide the use of sedation/anxiolysis in acute NIV. Their use in a critical care setting is reported to improve outcome and reduce patient distress (Level 2–).

Recommendations
7. Sedation should only be used with close monitoring (Grade D).
8. Infused sedative/anxiolytic drugs should only be used in an HDU or ICU setting (Grade D).
9. If intubation is not intended should NIV fail, then sedation/anxiolysis is indicated for symptom control in the distressed or agitated patient (Grade D).

Good practice point
In the agitated/distressed and/or tachypnoeic individual on NIV, intravenous morphine 2.5–5 mg (± benzodiazepine) may provide symptom relief and may improve tolerance of NIV.

NIV complications
The reported rate of complications varies widely. One review gives an incidence between 30% and 50%, the range partly depending on how a complication is defined. Extended duration of NIV, patient agitation and the frequent need to adjust mask fit are all associated with an increase in rate/severity of mask-related problems.

Nasal bridge ulceration is the most common problem (5–10%) and may be severe enough to result in NIV failure. Over-tightening is a common cause. NIV masks are designed to mould to the face when pressurised which over-tightening impairs. Should signs of skin trauma become apparent, a barrier dressing and a strategy of regular breaks and alternating between two interface types should be used. Latex allergy occasionally results in florid skin reactions. Some patients seem especially prone to mask-related rash even in the absence of allergy. Topical steroids may be indicated and/or antibiotics if the wound becomes infected.

NIV may cause severe gastric distension. It usually indicates poor coordination between patient and ventilator and it may be necessary to insert a nasogastric tube. Sinus or ear discomfort and nasal mucosal congestion or drying/ulceration can all occur. The value of humidification in preventing these side effects is uncertain but water-based nasal gels and topical corticosteroids or decongestants can be used. Petroleum-based emollients should not be used with supplemental oxygen.

An acute pneumothorax may be life-threatening but difficult to detect. The development of unexplained agitation/distress or chest pain requires this complication to be excluded. Co-existent interstitial lung disease or previous episodes of spontaneous or ventilator-induced pneumothorax increase the risk. Using a lower IPAP to avoid large tidal volumes, and a lower EPAP to avoid significantly increasing end-expiratory lung volume (EELV), are logical but not evidence based. If a pneumothorax develops, intercostal drainage is usually required.
Good practice points

- Minor complications are common but those of a serious nature are rare. Patients should be frequently assessed to identify potential complications of NIV.
- Care is needed to avoid overtightening of masks.
- Previous episodes of ventilator-associated pneumothorax warrant consideration of admission to HDU/ICU and use of NIV at lower than normal inspiratory pressures.
- The development of a pneumothorax usually requires intercostal drainage and review of whether to continue with NIV.

Sputum retention

Sputum retention can be a precipitant for AHRF, can cause NIV to fail and is a common reason for respiratory distress post-extubation in patients initially managed by IMV. Excessive sputum production characterises bronchiectasis and CF, and complicates some patients with AECOPD. Promoting sputum clearance can be particularly challenging in those with NMD and in the morbidly obese. Techniques, such as manually assisted cough and mechanical insufflation-exsufflation (MI-E), aid sputum clearance in patients with NMD. However, in a study including patients with either scoliosis or COPD, MI-E reportedly had no benefit. In another RCT, the use of MI-E reduced post-extubation respiratory failure in a mixed group of patients including some with AHFR. This study also provided NIV to those in respiratory distress. The reader is referred to the BTS Physiotherapy Guidelines for more detailed information.

Mini-tracheostomy facilitates secretion clearance in the spontaneously breathing patient and may have a role when sputum retention is thought to be a major determinant of AHRF, such as in CF. It is not an easy technique to perform in the anxious and breathless patient and training opportunities are rare. Clinicians who insert percutaneous tracheostomies are best placed to provide a service and the HDU/ICU is the best environment in which to perform mini-tracheostomy. In an attempt to avoid intubation, a combination of respiratory support by NIV and suctioning via a mini-tracheostomy has been described. This probably only has application if IMV is not desired by the patient as, in most such cases, IMV offers more chance of a successful outcome. In the patient initially managed by IMV, a mini-tracheostomy may be inserted at the time of endotracheal tube decannulation in patients with a high secretion load and/or a poor cough.

Evidence statements

Manual-assisted cough and MI-E are safe methods for aiding secretion clearance (Level 1+).

MI-E is more effective than manual-assisted cough in patients with stable NMD (Level 2+).

Mini-tracheostomy is a useful bedside procedure that can markedly improve secretion clearance, but requires patient cooperation and a skilled operator to be performed safely (Level 4).

Recommendations

10. In patients with NMD, mechanical insufflation and exsufflation should be used, in addition to standard physiotherapy techniques, when cough is ineffective and there is sputum retention (Grade B).

11. Mini-tracheostomy may have a role in aiding secretion clearance in cases of weak cough (NMD/CWD) or excessive amounts (COPD, CF), (Grade D).

Modes of IMV

Critical care ventilators are complex devices capable of delivering multiple modes. The traditional divide between pressure and volume has become blurred and hybrid modes combine aspects of both. Most patients with AHRF do not require sophisticated modes of providing IMV.

Initially, when airway resistance is high and/or compliance is low (eg, in asthma, CF or bronchiectasis) a period of mandated or ‘controlled mechanical ventilation’, often combined with deep sedation to reduce spontaneous breathing effort, allows time for bronchodilators, steroids and antibiotics to treat airway inflammation, overcome infection and for ‘bronchial toilet’ to be provided. These considerations also variably apply to the restrictive causes of AHRF. In addition, poor triggering, because of muscular weakness, is a risk in patients with NMD in whom a prolonged period of controlled mechanical ventilation may be necessary. In all patients with AHRF, allowing restorative sleep is important.

Management should shift towards supporting rather than mandating the pattern of ventilation as recovery begins. If there is adequate spontaneous effort, and the RR is not excessive, a switch to PS is recommended to reduce the need for sedation and also as the risk of respiratory muscle wasting may be reduced by establishing early spontaneous breathing. The concept that suppressing spontaneous breathing is causally related to diaphragm wasting is contentious in the literature. Space constraints prevent a fuller examination. One initially compelling human study that claimed to have demonstrated ‘disuse atrophy’ was subsequently critised because the diaphragms had been denervated. A study in patients with adult respiratory distress syndrome (ARDS) reported that those patients allowed to breathe spontaneously had less need for sedation than patients treated with controlled IMV, a reduced requirement for vasopressors, fewer days of ventilatory support, earlier extubation and a shorter length of ICU stay. This strategy has not been assessed in AHFR.

Invasive ventilation strategy

In obstructive causes, tidal volume (Vt) is limited by the airflow obstruction and compounded by the mechanical disadvantage of hyperinflation. The use of high inflation pressures, to achieve a ‘normal’ Vt, risks dynamic hyperinflation. It most dramatically occurs soon after intubation but may develop on switching ventilation mode, for example, from controlled to assisted ventilation.

The adverse consequences of hyperinflation include barotrauma, impaired gas exchange and patient discomfort. The increased intrathoracic pressure impedes venous return and increases right ventricular afterload with a resulting fall in cardiac output and hypotension.

Prolonging expiratory time limits gas trapping and is achieved by shortening the inspiratory time and reducing the minute volume, an approach recommended in airflow obstruction. If significant gas trapping still occurs, the recommendation is to use a lower than normal Vt in combination with a low RR and...
a more prolonged expiratory phase. This can often only be achieved using a controlled ventilation mode combined with deeper levels of sedation. On switching to PS (assist) during recovery, the inspiratory pressure needs to be sufficient to provide adequate tidal volume but not excessive. Settings therefore need to be individually adjusted and require regular review.

In ARDS, over-distention and repetitive recruitment/de-recruitment of lung units causes alveolar damage (so-called ventilator-induced lung injury) and may even provoke systemic inflammation. One explanation for improved outcome with low VT ventilation (<6 mL/kg), compared with conventional practice, may be avoidance of ventilator-induced lung injury. The ARDS literature provides evidence for permissive hypercapnia, demonstrating that a pH above 7.2 is well tolerated. This is the consensus target when pH control is difficult. Allowing permissive hypercapnia will result in cerebral vasodilation and a rise in intracranial pressure and may also compromise myocardial contractility. Attempts to raise pH to >7.2 may, however, compound hyperinflation and barotrauma. In ARDS, a peak airway pressure of 30 cm is the usual trigger for employing permissive hypercapnia, a strategy that reduces mortality.

In AECOPD, attempts to rapidly restore PaO2 and PaCO2 to normal are unnecessary. Although there is little evidence to provide guidance, it is suggested that the higher the pre-morbid PaCO2 (inhaled by a high admission bicarbonate), the higher the target PaCO2 should be. Recovery from extreme levels of hypercapnia is recognised. Any metabolic causes of acidosis, for example, from insulin insensitivity or excessive B2 stimulated glycogenolysis, should be treated separately.

In NMD, an adequate tidal volume can be achieved with relatively low inflation pressures (eg, 10–15), but higher pressure is needed in CWD because of reduced chest wall compliance. Lung recruitment strategies (ie, increasing PEEP) should be considered when there is persisting hypoxia and/or evidence of premature small airway closure in dependent lung tissue. Controlled MV may need to be continued in NMD when triggering is likely to be inadequate or tiring. Reducing the bicarbonate buffering capacity will require a period of relative hyperventilation when hypercapnia is chronic. The resulting urinary bicarbonate loss resets central respiratory drive. Carbonic anhydrase inhibitors can be used but caution is needed as high doses produce unpredictable effects through central stimulation of breathing.

Evidence statements

In ARDS, a low VT strategy improves survival (Level 1+). In airflow obstruction, prolonging the expiratory time reduces dynamic hyperinflation (gas-trapping) (Level 2+).

Oxygenation: SaO2 88–92% (except asthma when >96% recommended)
Acid base balance: pH 7.2–7.4 (permissive hypercapnia if inspiratory airway pressure > 30)
Tidal volumes: 6–8mL/kg
Respiratory rate: 10–15
I:E ratio: 1:2–1:4

Recommendations for IMV in obstructive disease

14. During controlled ventilation, dynamic hyperinflation should be minimised by prolonging expiratory time (I:E ratio 1:3 or greater) and setting a low frequency (10–15 breaths/min) (Grade C).
15. Permissive hypercapnia (aiming for pH 7.2–7.25) may be required to avoid high airway pressures when airflow obstruction is severe (Grade D).
16. Carbonic anhydrase inhibitors should not be used routinely in AHFR. (Grade C).

Positive end expiratory pressure

PEEP is an area of physiology that causes confusion among healthcare professionals. The best way to set optimal PEEP remains contentious. Simply stated, PEEP shifts the lungs to a more compliant portion of the pressure-volume curve. In restrictive causes of AHFR, lung volume is usually reduced and there may be dependent lung that is poorly ventilated or in which there is no effective alveolar ventilation. In these circumstances, increasing external PEEP increases VT for a given inspiratory pressure, will reduce PaCO2 and improve oxygenation. In obstructive disease, PEEP improves inspiratory airflow, limits dynamic hyperinflation and improves alveolar ventilation.

Dynamic hyperinflation may be suspected by a progressive fall in tidal volume with constant ventilator pressure settings (or, with volume control, an increase in inflation pressure) and by signs of increasing patient distress such as tachycardia and hypotension.

The degree of intrinsic PEEP (iPEEP) can be estimated by examination of the expiratory flow curve and pressure or be measured invasively. Active expiratory muscle contraction, common in airflow obstruction, will artificially increase apparent iPEEP. Levels of iPEEP in obstructive airways disease have been reported to range from 4.6 to 13.6 cm H2O.

Setting the PEEP level in excess of iPEEP may be deleterious. This has led to the recommendation that PEEP be set at 50–80% of iPEEP. However, as the severity of airway obstruction in small airways will vary throughout the lung, a variable response to increasing the PEEP might be anticipated. If, on balance, an increase in ePEEP were to reduce overall airflow resistance then EELV will fall even though ePEEP apparently exceeds iPEEP.

Intrinsic PEEP is a pressure that must be overcome by patient effort before a breath can be triggered. It is, therefore, an inspiratory threshold load and may lead to ineffective triggering and patient discomfort. Offset setting iPEEP by increasing the ventilator PEEP will then reduce the effort of triggering and...
improve patient–ventilator asynchrony.118–120 It is important to appreciate that the same pathophysiological processes occur during treatment with NIV when a higher EPAP setting may improve triggering, patient comfort and oxygenation.

**Evidence statement**

In obstructive causes of AHRF, PEEP may increase tidal volume, improve compliance and reduce airflow obstruction (Level 2+). Setting PEEP greater than iPEEP can be harmful (Level 2+).

In restrictive causes of AHRF, PEEP may assist in lung recruitment, improve compliance and correct hypoaxaemia (Level 3).

**Recommendation**

17. Applied ePEEP should not normally exceed 12 cm (Grade C).

**Sedation in IMV**

Patients receiving IMV require sedation, especially before stability is achieved.89 Most ICUs use Propofol or a benzodiazepine, either alone or in combination with an opioid. Benzodiazepines with inactive metabolites and/or short acting synthetic opioids have been recommended to avoid over-sedation.121 122 Although sedation increases IMV tolerance, over-use is associated with adverse outcomes such as prolonged duration of IMV, increased ICU length of stay and delirium.123

To avoid this, withholding of further sedation until an objective degree of wakefulness develops has been investigated. In two trials, this strategy was shown to reduce duration of IMV and ICU length of stay.124 125 Studies employing sedation protocols targeting specific (higher) levels of alertness have also reported a reduction in duration of IMV, ICU and hospital length of stay.126–129 However, a meta-analysis of RCTs on sedation breaks demonstrated safety but failed to confirm benefit130 and a more contemporary RCT, combining protocolised sedation with daily breaks, also found no benefit.131 No study has shown harm from sedation breaks. The effect of stopping or reducing sedation on patient experience has not been reported.

**Evidence statements**

Daily interruption of sedation is safe and may reduce the duration of IMV and ICU length of stay (Level 1+).

Sedation protocols that target specific levels of alertness may reduce duration of IMV and ICU length of stay (Level 1+).

**Recommendation**

18. Sedation should be titrated to a specific level of alertness (Grade B).

**Patient–ventilator asynchrony**

Patient–ventilator asynchrony is common and increases patient discomfort, the work of breathing, the need for sedation, the incidence of confusion, the need for tracheostomy and the mortality rate.112 113 The commonest cause is ineffective triggering due to either respiratory muscle weakness and/or excessive effort required to overcome iPEEP and trigger a breath.134 ‘Trigger failure is more common during sleep and more likely if hypercapnia persists by day. A hybrid mode, such as PS with a mandatory backup rate is recommended in these circumstances to avoid pCO2 increasing during sleep.

Auto triggering refers to inappropriately delivered breaths being provided by the ventilator. It can be provoked by patient movement, suctioning, coughing and swallowing, and is more likely when the trigger sensitivity is set too high. Both a delay in the onset of a triggered breath or an inadequate amount of PS to sufficiently augment inspiratory flow can lead to an unpleasant sensation best described as ‘air hunger’. This can be difficult to detect or for the patient to report. Experienced NIV practitioners may trial increasing trigger sensitivity and/or PS, and monitor the effect on patient comfort and RR. If inadequate PS is given, the breathing rate will fall. The detection of the more subtle forms of patient–ventilator asynchrony requires examination of the pressure/flow waveforms.135 The most sensitive measure of patient–ventilator asynchrony is by simultaneous recordings of diaphragm electrical activity and pressure changes in the oesophagus.136 Flow rather than pressure triggers reduce the incidence of asynchrony,136 137 as has the move away from volume-controlled ventilation.138 139

Proportional assist ventilation (PAV) and neurally adjusted ventilatory assist (NAVA) are modes that are being assessed as ways to reduce patient–ventilator asynchrony. With PAV, the degree of pressure support is determined, on a breath by breath basis, by the patient’s inspiratory effort.140–143 Compared with PS, PAV has been reported to reduce the probability of returning to a controlled mode and the incidence of patient–ventilator asynchrony.144 In NAVA, the ventilator attempts to match neural drive by adjusting the degree of PS (within safe limits), using the electrical activity of the diaphragm to ‘drive’ the ventilator. Studies comparing patient–ventilator interaction show a reduction in triggering delay with NAVA, reduced cycling delay and a reduction in asynchrony events.144 145 Uncertainties persist on how to adjust the NAVA level and this technical issue is currently frustrating efforts to demonstrate clinical benefit.

It is important to emphasise that patient ventilator asynchrony is common with NIV. While the same principles apply it has been less frequently recognised or investigated. It can critically affect the success of NIV and the patient experience (see below).

**Evidence statements**

Patient–ventilator asynchrony is common and deleterious, and can be minimised through informed adjustment of ventilator settings (Level 2+). Proportional and NAVA have been shown experimentally to reduce ventilator asynchrony but have yet to improve patient outcome (Level 2+).

**Recommendations**

19. Ventilator asynchrony should be considered in all agitated patients (including NIV) (Grade C).

20. As patients recover from AHRF, ventilator requirements change and ventilator settings should be reviewed regularly (Grade C).

**Use and timing of a tracheostomy**

It is accepted that tracheal intubation beyond 10 days can be detrimental.146 147 Historically, it was believed that early tracheostomy reduced ventilator time and ICU length of stay.148 A survey of ICU physicians in 2005 found that 61% of respondents would perform a tracheostomy without first performing a trial of extubation and 50% favoured tracheostomy insertion within the first week.149 Two large multicentre studies have failed to show benefit from tracheostomy performed within 7 days of admission.150 151 A subsequent meta-analysis also reported no effect on the incidence of ventilator-associated pneumonia or mortality.152 Although less sedation was required after a tracheostomy had been inserted.153 Tracheostomy carries a morbidity and mortality risk at the time of insertion154 and subsequently.155 A UK national report has highlighted the risk of critical airway incidents in patients with tracheostomies.155 Accordingly, consideration of the risk and benefit should be undertaken before proceeding to insert a tracheostomy and due consideration should be given to using NIV post-extubation to avoid a tracheostomy. This is particularly the case in progressive NMD/CWD when tracheostomy insertion carries the risk of permanence. These aspects, and the evidence summarised...
below, are considered further in Management of hypercapnic respiratory failure section.

**Evidence statement**

Early insertion of a tracheostomy does not reduce mortality, duration of IMV, or the incidence of ventilator-associated pneumonia (Level 1++).

**Recommendations**

21. Performing routine tracheostomy within 7 days of initiating IMV is not recommended (Grade A).

22. The need for and timing of a tracheostomy should be individualised (Grade D).

**Good practice points**

- In AHRF due to COPD, and in many patients with NMD or OHIS, NIV-supported extubation should be employed in preference to inserting a tracheostomy.
- In AHRF due to NMD, alongside discussion with the patient and carers, the decision to perform tracheostomy should be multidisciplinary and should involve discussion with a home ventilation unit.

**MANAGEMENT OF AHRF**

**Obstructive lung diseases**

Acute exacerbations of COPD account for 100 000 admissions annually in England. Of these, around 20% will present with or develop hypercapnia, an indicator of increased risk of death. The development of AHRF is often multifactorial. These include infection, mucosal oedema, bronchospasm, sputum retention, excessive O_{2} therapy, sedation, pneumothorax, PE and left ventricular failure. Since the publication of the BTS guideline in 2002 and subsequent National Institute for Health and Care Excellence (NICE) recommendations, the use of NIV in AECOPD has increased and most hospitals admitting unselected medical patients are able to provide an NIV service.

Prevention of AHRF in AECOPD

There is compelling evidence that uncontrolled oxygen therapy increases the degree of acidosis and subsequent mortality in AECOPD. In a trial comparing the use of high concentration oxygen versus titrated oxygen in 405 individuals with presumed AECOPD in the pre-hospital (ambulance/paramedic) setting, Austin et al reported that titrated oxygen reduced mortality by 58% for all patients (relative risk 0.4) and by 78% for patients with confirmed COPD (RR 0.22). Patients with COPD who had received titrated oxygen according to the protocol (targeted at a saturation of 88–92%) were less likely to have respiratory acidosis (mean difference in pH 0.12) than those who received high-concentration oxygen. These data provide further evidence to titrate oxygen treatment to a modest target saturation in patients with breathlessness and a history or clinical likelihood of COPD. Importantly, the mechanism(s) of oxygen-induced hypercapnia apply, to varying degree, in the other causes of AHRF. Accordingly, the same oxygen saturation target is recommended in the initial management of all patients at risk of AHRF.

**Evidence statement**

The use of controlled oxygen therapy in individuals with suspected AECOPD reduces mortality and the frequency and severity of AHRF (Level 1++).

**Recommendation**

23. In AHRF due to AECOPD, controlled oxygen therapy should be used to achieve a target saturation of 88–92% (Grade A).

Good practice point

Controlled oxygen therapy should be used to achieve a target saturation of 88–92% in ALL causes of AHRF.

**Role of NIV in AECOPD**

There are three clinical situations in which NIV is recommended in AECOPD. First, the patient with a modest respiratory acidosis with the aim of preventing deterioration to a point when IMV would conventionally be considered. Second, as an alternative to IMV when conventional criteria for IMV are met (lower pH, more distress) with the intention to proceed to IMV if NIV fails. Third, as the ‘ceiling’ of treatment for patients who, for whatever valid reason, are not candidates for IMV. The evidence base for NIV has rarely defined the particular patient case mix in this way.

There have been many trials of NIV in acidotic AECOPD, including 21 where NIV was compared to standard non-ventilatory treatment, one trial of NIV versus sham NIV and two trials of NIV versus IMV. Five of the studies were conducted in an ICU setting, one in the pre-hospital setting, two in emergency departments (EDs), two in HDUs and the remainder in general wards. In general, patients in studies conducted in the ICU had lower pH and therefore more severe exacerbations.

In a meta-analysis of NIV use versus usual care, NIV was associated with a lower mortality (relative risk 0.41), a lower need for intubation (relative risk 0.42), lower likelihood of treatment failure (relative risk 0.51) greater improvements at 1 h in pH (weighted mean difference 0.03), P_{CO_{2}} (weighted mean difference −0.40 kPa) and RR (weighted mean difference −3.08 breaths/min). NIV also resulted in fewer treatment-associated complications (relative risk 0.32) and a shorter duration of stay in hospital (weighted mean difference 3.24 days).

In one trial, NIV was compared to IMV for AECOPD after a failure of standard medical treatment. There was no difference in survival. However, in those patients in whom NIV was successful, duration of hospital stay was shorter, there were fewer complications, fewer patients required de novo oxygen supplementation and there were fewer readmissions to hospital in the following year.

No trial has demonstrated a worse outcome with NIV compared to non-ventilatory management, although, in one study, NIV use may have caused a delay in escalation to IMV. The danger that the use of NIV may inadvertently lead to a worse outcome is, however, suggested by a large American retrospective study. Chandra et al reported on an estimated 7.5 million admissions for AECOPD in the USA between 1998 and 2008. During this period, there was a 460% increase in the use of NIV and a 42% decline in IMV use. Worryingly, given the increasing familiarity of staff using NIV over time, the number of patients failing NIV and requiring IMV increased as did hospital mortality. By 2008, NIV failures had a 29% risk of death, a 60% greater risk than patients managed by immediate intubation and provision of IMV. NIV failures, who were then managed by IMV, had a sevenfold greater risk of death than patients successfully treated by NIV. Possible explanations include the fact that further physiological deterioration may have resulted from the delay in the institution of IMV in NIV failures and/or that patients who fail NIV are more severely ill.

The outcomes in AECOPD reported in the UK National COPD Resources and Outcomes project (NCROP) are also of concern, as NIV outcome was less favourable than reported in the RCTs discussed above. The low level of ICU involvement...
and/or use of IMV reported has led to the suggestions that the clinical environment in which NIV was delivered was inadequate for the level of patient complexity/acid–base disturbance, that there was an over-reliance on the effectiveness of NIV and an under recognition of NIV failure.7 Similar conclusions can be drawn from BTS NIV audits. In the most recent survey, carried out in 2013, median pH was 7.24 and yet NIV was provided outside of HDU/ICU in 91%. In the AECOPD group (61% of AHRF cases), overall mortality was 28% in those admitted to HDU/ICU and 40% for those admitted to wards.9 See Care planning and delivery of care section for further consideration of the possible unintended consequences of the introduction of NIV in managing AHRF.

In around 20% of AHRF cases secondary to AECOPD, optimised medical treatment, which includes targeting an oxygen saturation to 88–92%, will result in normalisation of arterial pH.2 62 Established guidance is therefore to await improvement and initiate NIV if, after 60 min, the following are present: pH <7.35, pCO2 >6.5 kPa and RR >23 breaths/min.1 68 There is some evidence that NIV may also be beneficial in patients with hypercapnia in the absence of acidosis. A study from China162 showed a reduction in the need for endotracheal intubation in a subgroup analysis of patients with hypercapnia but a pH >7.35 (9/80 vs 2/71, p=0.04). However, length of stay and duration of NIV were longer than in a similar UK study,163 and there was a high incidence of side effects, particularly gastric distension (23%), despite low pressure being used (IPAP 12±4). It is unclear if this study is applicable to UK practice.

There is insufficient evidence to support the use of absolute values of pH or pCO2 as an indication for IMV rather than NIV.164 Nevertheless, a pH of 7.25 has been suggested as a threshold level below which IMV should be considered. NIV may still be effective at reversing such severe acidosis but the failure rate is higher.158 Evidence statements

Optimal medical therapy, including controlled oxygen therapy, leads to a resolution of respiratory acidosis in 20% of individuals with AECOPD (Level 1+).

Compared with standard medical therapy, NIV improves survival, reduces the need for endotracheal intubation, reduces complications and reduces length of stay (Level 1+).

There is no lower limit of pH below which a trial of NIV has been shown to be harmful (Level 2±+).

Continued use of NIV when the patient is deteriorating, rather than escalating to IMV, increases mortality (Level 2+).

Audit data show that ‘real world’ outcomes do not reproduce those demonstrated in the RCTs (Level 2+).

One risk of an expansion of ward-based rather than HDU/ICU provision of NIV may be greater delay in expert review and/or escalation to IMV (Level 4).

Recommendations

24. For most patients with AECOPD, the initial management should be optimal medical therapy and targeting an oxygen saturation of 88–92% (Grade A).

25. NIV should be started when pH<7.35 and pCO2>6.5 kPa persist or develop despite optimal medical therapy (Grade A).

26. Severe acidosis alone does not preclude a trial of NIV in an appropriate area with ready access to staff who can perform safe endotracheal intubation (Grade B).

27. The use of NIV should not delay escalation to IMV when this is more appropriate (Grade C).

28. The practice of NIV should be audited regularly to maintain standards (Grade C).

Starting NIV in COPD

Recommendations regarding investigations before starting NIV are based on expert opinion. ABG measurement is required to diagnose and quantify the severity of AHRF, and a chest radiograph is needed to seek evidence of causation or complications. To avoid any delay in giving ventilatory support, NIV should be initiated in extreme acidosis (pH<7.25) without waiting for a chest X-ray. Other investigations (eg, full blood count (FBC), U+E, ECG) should be performed and treatment directed at any reversible factors contributing to AHRF. In some cases, echocardiography may be indicated to exclude acute pulmonary oedema. As is further discussed in Care planning and delivery of care section, it is recommended that an action plan be agreed in the event of NIV failure and that this is documented at the start of treatment.

Good practice points

- ABG measurement is needed prior to and following starting NIV.
- Chest radiography is recommended but should not delay initiation of NIV in severe acidosis.
- Reversible causes for respiratory failure should be sought and treated appropriately.
- At the start of treatment, an individualised patient plan (involving the patient whenever possible) should document agreed measures to be taken in the event of NIV failure.

Prognostic features relating to use of NIV in COPD

The 2003 UK National COPD audit165 demonstrated a higher hospital mortality in patients with a lower admission pH and oxygen saturation, higher urea, lower albumin and older age (see below for further discussion), irrespective of treatment modality. Increased base excess (indicating chronicity of hypercapnia), MRC dyspnoea index and RR are additional prognostic variables.165 166 The presence of pulmonary consolidation on X-ray and impaired consciousness level (GCS<8) increase the NIV failure rate,167 although successful outcome despite impaired consciousness has been reported.49 168

In contrast, Nava et al169 reported a good outcome for patients aged >75 years, in terms of intubation avoidance and reduced mortality with NIV. Others have also achieved satisfactory results in the elderly.170 However, in a retrospective analysis of 240 ward-based cases from a single centre, age >75 years was associated with poorer outcomes with NIV.171

The NCROP audit, which collected data on 9716 AECOPD admissions, reported mortality at 12% when the presentation pH was the lowest value reached, 24% when acidosis increased after presentation and 33% when acidosis only developed after admission.7 These findings reflect a combination of increasing severity of illness and a lack of response to standard medical treatment. In addition, delay in providing therapeutic NIV and/or IMV contributed. The audit also highlighted that a coincident metabolic acidosis was an adverse finding.

Once NIV has been initiated, a reduction in RR and improvement in pH within 4 h predicts NIV success.172 Associated features are a reduction in signs of respiratory distress, reduced anxiety or agitation and a decrease in heart rate. In one large study, Confalonieri et al173 showed that, if pH <7.25 and RR >35 persist, NIV failure is likely. Worsening acidosis, after initial improvement with NIV, is also associated with a worse prognosis.174–176 In a case series published by Moretti et al,20% of patients deteriorated after initially improving with NIV. In these circumstances, prognosis was poor whether patients were subsequently intubated or continued with NIV.177
Roche Campo et al. found that polysomnographic evidence of severe sleep disturbance in patients with COPD with AHRF correlated with a poor outcome and GurSel et al., reporting on a retrospective analysis of patients with COPD and OHS treated in an ICU setting, found better outcome in patients receiving pressure control rather than overnight PS. Clinical research in stable sleep hypoventilation also suggests that limiting the increase in hypercapnia during sleep is important and that a controlled ventilation mode may be more advantageous than the assist mode.

Evidence statements

Advanced age is not an important determinant of outcome with NIV treatment of AHRF (Level 1+).

An improvement in physiological parameters, usually within 1–2 h, particularly pH and RR, predict a successful outcome from NIV treatment (Level 1+).

Worsening of physiological parameters, particularly pH and RR, is predictive of an increased risk of death and/or requirement for intubation (Level 1+).

Recommendations

29. Advanced age alone should not preclude a trial of NIV (Grade A).

30. Worsening physiological parameters, particularly pH and RR, indicate the need to change the management strategy. This includes clinical review, change of interface, adjustment of ventilator settings and considering proceeding to endotracheal intubation (Grade A).

Good practice points

If sleep-disordered breathing pre-dates AHRF, or evidence of it complicates an episode, the use of a controlled mode of NIV overnight is recommended.

Duration of NIV in COPD

Normalisation of pH and a pCO2 <6.5 are commonly used as a guide to the discontinuation of NIV. Restoring respiratory drive will require a prolonged period of NIV to reduce the pCO2 than to correct the acidosis.

The optimal amount of NIV in the initial period, and the most effective way to withdraw it as the patient improves, have not been examined in published trials. As the work of breathing falls and acute hyperinflation reverses, as a result of treatment with steroids, antibiotics and intense bronchodilator therapy, unsupported alveolar ventilation will return towards normal. The more florid the evidence for infection precipitating AHRF, the more likely there is to be full reversal. Normalisation of pCO2 may not be possible in some patients, particularly those who show evidence of chronic hypercapnia at presentation.

In most RCTs, the intention has been that patients should receive continuous NIV for the first 24 h. The amount of NIV actually delivered, when this has been reported, has been less than planned, from a median of 20 h in one study to 7 h in another. Conventional practice is to gradually reduce the amount of time on NIV with increasingly prolonged periods of self-ventilation during the day, while continuing with NIV overnight. Monitoring of pCO2 on and off NIV is a useful guide to how quickly the withdrawal of NIV can proceed. Transcutaneous pCO2 measurement may facilitate this better than continuing with arterial or capillary sampling. A gradual reduction of ventilator pressures, and a switch to PS or a reduction in backup rate, should mirror patient recovery. Attempts to adjust ventilator settings to achieve patient comfort remain important. Those with a less clear infective cause for AHRF, and/or evidence of chronicity of hypercapnia, should be assessed for alternative or additional causative factors such as marked fluid retention, obstructive sleep apnoea (OSA) or OHS. One study suggested there may be an advantage to employing NIV for longer than the conventional 3 days. More trial data are needed to guide optimal withdrawal of NIV.

Evidence statement

In clinical trials, NIV has been discontinued when there has been normalisation of pH and pCO2 and a general improvement in the patient’s condition (Level 1+).

Recommendation

31. NIV can be discontinued when there has been normalisation of pH and pCO2 and a general improvement in the patient’s condition (Grade B).

Good practice points

- Time on NIV should be maximised in the first 24 h depending on patient tolerance and/or complications.
- NIV use during the day can be tapered in the following 2–3 days, depending on pCO2 self-ventilating, before being discontinued overnight.

Optimising NIV delivery and technical considerations

The commonest reasons for failure of NIV are excessive mask leak, insufficient PS and ventilator patient asynchrony. If the PS is inadequate, alveolar ventilation will not be significantly increased. This may be detected by a lack of augmentation of chest and abdominal wall movement. National NIV audits have revealed that inadequate IPAP is often used in AECOPD. In general, while a patient might be started on NIV with an IPAP of 15, this should be progressively increased to reach an IPAP of 20–30 within 10–30 min, the need for higher pressure and a more rapid escalation being indicated by patient size and more severe acidosis, respectively.

In the presence of persisting hypoxaemia, that is thought unrelated to sputum retention, the EPAP may need to be increased in an attempt to recruit areas of poorly ventilated lung. (It may also be appropriate if there is a degree of upper airway obstruction). If ineffective, or if this results in distress, senior review is indicated while the FiO2 is temporarily increased.

Leak should always be minimised by mask adjustment and/or by changing the mask type. Positional upper airway obstruction may result in ineffective NIV. It is often indicated by variable mask leak. Care is needed to ensure head flexion is avoided.

---

Table 3 Technical issues: a guide for when NIV is failing

<table>
<thead>
<tr>
<th>Problem</th>
<th>Cause(s)</th>
<th>Solution(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ventilator cycling independently of patient effort</td>
<td>Inspiratory trigger sensitivity is too high; Excessive mask leak</td>
<td>Adjust trigger; Reduce mask leak</td>
</tr>
<tr>
<td>Ventilator not triggering despite visible patient effort</td>
<td>Excessive mask leak; Inspiratory trigger sensitivity too low</td>
<td>Reduce mask leak; Adjust trigger for NM patients consider switch to PCV</td>
</tr>
<tr>
<td>Inadequate chest expansion despite apparent triggering</td>
<td>Inadequate Tidal volume</td>
<td>Increase IPAP. In NM or chest wall disease consider longer Ti</td>
</tr>
<tr>
<td>Chest/abdominal paradox</td>
<td>Upper airway obstruction</td>
<td>Avoid neck flexion; Increase EPAP</td>
</tr>
<tr>
<td>Premature expiratory effort by patient</td>
<td>Excessive Ti or IPAP</td>
<td>Adjust as necessary</td>
</tr>
</tbody>
</table>

---

EPAP, expiratory positive airway pressure; IPAP, inspiratory positive airway pressure; NIV, non-invasive ventilation; NM, neuromuscular; PCV, pressure-controlled ventilation.
particularly in sleep. Patient–ventilator asynchrony may be caused by mask leak, insufficient or excessive IPAP inappropriate setting of Ti or Te, high levels of intrinsic PEEP or excessively sensitive triggers. If the cause is unclear, advice should be sought from an experienced NIV practitioner.

Although there is no agreed definition of NIV failure, it is suggested by persisting or worsening of acidosis despite attempts to optimise NIV delivery. In these circumstances, further advice should be sought as soon as possible. NIV failure is associated with low/falling pH172 and a high APACHE II score.180 Persisting with ineffective NIV adds to patient discomfort and, if IMV is indicated, risks further patient deterioration and cardiorespiratory arrest. Evidence that this risk is real comes from the use of NIV in post-extubation respiratory failure where delay in re-intubation, caused by persisting with NIV when ineffective, increased mortality.181 If NIV is adding to patient distress, and intubation has been deemed to be inappropriate (see below), NIV should be discontinued and palliative care measures adopted.

**Good practice point**

Before considering NIV to have failed, check that common technical issues have been addressed and ventilator settings are optimal.

**Indications for IMV in AECOPD**

Intubation should be immediately considered for patients presenting with or developing respiratory arrest, gasping respiration, a pH <7.15 or showing signs of a low cardiac output. Intubation may also be appropriate if NIV is contra-indicated or technically impossible and when NIV has been tried but has failed.

There is insufficient evidence to support the use of absolute values of pH or pCO2 as intubation criteria and it is unlikely that any absolute value would be applicable to all patients in all situations.164 Nevertheless, pH<7.25 has been suggested as a level below which IMV should be considered and <7.15 as the level that IMV is indicated (following initial resuscitation and use of controlled oxygen).

In the UK, only a small proportion of patients receiving NIV treatment escalate to IMV despite data suggesting more should do so.3 4 7 A degree of unjustified ‘therapeutic nihilism’ may have shaped UK IMV practice. Duration of ICU stay and survival in AECOPD is better than most other medical causes for which invasive ventilation is employed.6 In a prospective cohort study, clinicians’ estimated prognosis for patients with AECOPD or chronic asthma was lower than indicated by predictive modelling.182

Specialist support to staff providing NIV may reduce mortality. In one study, employing critical care outreach nurses, the mortality was reduced from 57% to 35%. This was in part due to a greater number of patients receiving IMV183. Validated prognostic scoring tools (see next section) may aid discussion regarding intubation. Box 1 summarises the indications for IMV in AECOPD.

**Evidence statements**

Intubation is indicated if NIV is failing (unless it is agreed that this is not desired by the patient or it is deemed not in the patient’s ‘best interest’) (Level 1+).

Neither patient characteristics nor pathophysiological parameters are sufficiently robust to predict the success of NIV or IMV but, in general, the more adverse features that are present and the greater the physiological disturbance the higher the chance of treatment failure or death (Level 2+).

**Recommendations**

32. IMV should be considered if there is persistent or deteriorating acidosis despite attempts to optimise delivery of NIV (Grade A).

33. Intubation should be performed in respiratory arrest or peri-arrest unless there is rapid recovery from manual ventilation/provision of NIV (Grade D).

34. Intubation is indicated in management of AHRF when it is impossible to fit/use a non-invasive interface, for example, severe facial deformity, fixed upper airway obstruction, facial burns (Grade D).

35. Intubation is indicated where risk/benefit analysis by an experienced clinician favours a better outcome with IMV than with NIV (Grade D).

**Outcome following NIV or IMV in AECOPD**

There are a number of tools that may inform discussion regarding prognosis in COPD. Some were developed for use in the stable setting, such as the BODE index184 and the DECAF score.185 APACHE II, a generic acute physiology score, was developed using parameters available at ICU admission. Despite being generic, it retains predictive value of mortality in AECOPD.180 186 187 Wildman et al188 analysed a large UK ICU clinical database (with a 35% mortality) to develop a disease-specific score, the COPD and Asthma Physiology Score (CAPS). This was based on 8, mainly biochemical, variables. CAPS was reported to perform better than generic scoring. The authors acknowledge that normal functional assessment, for example, by body mass index (BMI), usual functional status and presence of comorbidity, might improve predictive power.

Confalonieri et al189 suggested that prognosis following successful use of NIV in AHRF was better than if IMV were employed. The number and length of further hospitalisations were significantly higher and the survival rate at 12 months significantly lower (50% vs 71%) than in patients who received NIV. Follow-up of patients in the RCT of Plant et al172 showed a median survival of 16.8 months in those treated with NIV and 13.4 months in those receiving standard treatment (p=0.12). The trend in improved survival was attributable to prevention of death during the index admission.

A study of an inception cohort of 73 106 patients with COPD, followed up after their first AHRF treated by NIV, reported a 2-year survival of 70% and a median survival of 3.6 years.190 After a second hospitalisation, patients typically entered a deteriorating pattern with more frequent and severe episodes until death. A retrospective analysis of 100 patients with COPD, followed up for up to 5 years after their first episode of NIV193 found that 52% survived 2 years. When the BMI was <22 kg/m2, age >75 years or there was prior home oxygen use, survival was only 26%. In a prospective cohort of patients with COPD surviving AHRF treated by NIV192 80% were re-admitted within a year, of whom 50% died. APACHE II score at admission, home oxygen prescription and a BMI below 25 predicted early recurrent AHRF or death.

**Box 1 Indications for invasive mechanical ventilation (IMV) in acute exacerbation of COPD (AECOPD)**

- Imminent respiratory arrest
- Severe respiratory distress
- Failure of or contra-indications to non-invasive ventilation (NIV)
- Persisting pH<7.15 or deterioration in pH despite NIV
- Depressed consciousness (Glasgow Coma Score <8)
In summary, an admission with AHRF is a critical point in the natural history of COPD, with a more accelerated decline in most patients following recovery. It indicates a high risk of recurrence of AHRF and poor long-term prognosis. Survival data vary between published studies, presumably a reflection of differences in case mix. Survival might be better if NIV is successfully employed for AHRF than if IMV is used. An important management point is that the first episode of AHRF should prompt a discussion about lifestyle, patient wishes for management of future episodes and discussions about end-of-life care generally.

There is evidence of ‘prognostic pessimism’ among clinicians caring for patients with AECOPD. In an outcome study of 517 patients, 62% survived to 180 days, yet overall predicted survival at the time of admission was 49%. For those considered to be in the worst prognostic group (a survival rate of 10%), 40% recovered. Accordingly, as survival from AECOPD becomes less likely, clinicians become worse at prediction and err on the side of underestimating survival. By implication, it is likely that patients who might otherwise survive are currently being denied admission to ICU because their survival potential is underestimated. Importantly, from a patient perspective, Wildman et al reported that the majority of patients surviving IMV for AHRF had stable and acceptable QoL despite poor health status and 96% stated they would opt for IMV again under similar circumstances.

Evidence statement
There are validated tools for the assessment of prognosis in stable and exacerbating COPD populations but, on their own, they are unreliable for individual prognostication (Level 2+). Physicians underestimate survival potential in AECOPD treated by IMV (Level 2+).

The majority of patients with COPD or chronic asthma who receive IMV would elect to receive it again (Level 2+).

An episode requiring ventilatory support generally indicates advanced disease with a high risk for future episodes of AHRF and a limited prognosis (Level 2++).

Recommendations
36. Prognostic tools may be helpful to inform discussion regarding prognosis and the appropriateness of IMV with the caveat that such tools are poorly predictive for individual patient use (Grade B).
37.Clinicians should be aware that they are likely to underestimate survival in AECOPD treated by IMV (Grade B).
38. Clinicians should discuss management of possible future episodes of AHRF with patients following an episode requiring ventilatory support because there is a high risk of recurrence (Grade B).

Acute asthma
Five small RCTs of NIV in acute asthma have been published. Four were conducted in the ED and one in a respiratory ICU. Importantly, none of the RCTs included patients with hypercapnia and intubation rates were low. Most showed treatment with NIV led to a faster improvement in FEV1 and a shorter ICU/hospital stay. They all have important design weaknesses. The trial by Soma et al lacked a second control arm (conventional inhaled bronchodilators) and the trial by Brandao et al did not give systemic steroids. No information was provided about acceptability of NIV to patients. The only study reporting use in asthma was a retrospective cohort study by Meduri et al of 17 patients with a mean pH of 7.25. NIV was reported to be successful in avoiding intubation in 15.

The use of NIV in acute asthma, particularly AHRF, needs to be set in the context of a very low mortality rate with IMV. There is also the potential for patients with acute asthma to deteriorate rapidly, to require high inflation pressures and a high inspired oxygen concentration. Trialling NIV therefore carries significant risk. The patient with brittle asthma or a very short history suggesting hyperacute bronchospasm, especially when oxygen toxicity in transit is implicated, might justify a trial of NIV in the resuscitation area but, in all other circumstances, ventilatory support should be by intubation and provision of IMV.

The overall invasive management of acute severe asthma is similar to that in AECOPD but a higher SaO2 target of 96% is advised. For more specialist consideration, the reader is referred to standard textbooks or recent reviews.

Acute (and chronic) hypercapnia may complicate chronic asthma, a condition that shares many features of COPD, such as chronic hyperinflation, persistent and only partially reversible airflow obstruction, mucus hypersecretion and infective exacerbations. As the pathophysiology is similar, the guidance on the use of NIV and IMV in AECOPD applies to the chronic asthmatic with AHRF.

Evidence statements
There is insufficient evidence to support the use of NIV in AHRF in acute asthma (Level 3).
IMV in acute asthma carries a very low mortality rate. Most asthma deaths relate to presentation in extremis or a failure to immediately implement IMV when indicated rather than a failure of IMV per se (Level 2+).

Recommendations
39. NIV should not be used in patients with acute asthma exacerbations and AHRF (Grade C).
40. Acute (or acute on chronic) episodes of hypercapnia may complicate chronic asthma. This condition closely resembles COPD and should be managed as such (Grade D).

Non-CF bronchiectasis
Recurrent episodes of hypercapnic respiratory failure may characterise bronchiectasis with periods of good or acceptable quality of life (QoL)/health status in the intervening months or years. In some, domiciliary ventilation will be indicated for symptoms of sleep disordered breathing. There are no RCTs of NIV versus IMV in acute exacerbations of bronchiectasis. The recommendations regarding NIV for AECOPD are appropriate although there is the additional challenge of excessive and difficult to clear sputum. NIV may relieve breathlessness and help patients to participate more effectively with physiotherapy. A mini-tracheostomy, or other techniques to aid sputum clearance, may be indicated.

There is scant data on outcomes for AHRF in non-CF bronchiectasis. In a retrospective review of patients managed by NIV (n=31) or IMV (n=26) for AHRF, the NIV group had less severe physiological disturbance. There was no difference in hospital mortality between the two groups (26% and 27%). The NIV failure rate (need for intubation, or death in the ICU) was 33%.

Using logistic regression, the APACHE II score was the only predictor of hospital mortality (OR 1.19 per point) and the severity of hypoxia (pO2/FiO2 ratio) the only predictor of NIV failure (OR 1.02/mm Hg decrease). Hospital mortality of patients with AHRF secondary to bronchiectasis is therefore approximately 25% whether management is by NIV or IMV. When selectively applied, NIV fails in one-third and this is predicted by the degree of hypoxaemia. Similar criteria should be used as in AECOPD when deciding appropriateness of intubation: health status, comorbidities, previous episodes of IMV and patient preferences. Evidence of an acute precipitating factor (infection) should favour intubation, as reversibility is more likely than in progressive chronic hypercapnia.
Evidence statements

In non-CF bronchiectasis and AHRF, NIV is indicated if there is respiratory acidosis using the same criteria as in AECOPD (Level 3).

Outcome with NIV is no worse than with IMV in selected patients (Level 2+).

Recommendations

41. In patients with non-CF bronchiectasis and AHRF, controlled oxygen therapy should be used (Grade D).
42. In patients with non-CF bronchiectasis, NIV should be started in AHRF using the same criteria as in AECOPD (Grade B).
43. In patients with non-CF bronchiectasis, NIV should usually be tried before resorting to IMV in those with less severe physiological disturbance (Grade C).
44. In non-CF bronchiectasis, the patient’s clinical condition prior to the episode of AHRF, and the reason for the acute deterioration, should be evaluated and used to inform the decision about providing IMV (Grade C).

Good practice points

- In patients with non-CF bronchiectasis, the precipitating cause is important in determining short-term prognosis.
- Health status prior to the episode of AHRF is an important predictor of outcome.

Cystic fibrosis

Recurrent episodes of acute on chronic hypercapnic respiratory failure characterise advanced CF, such episodes usually being precipitated by infection. There may be intervening months of acceptable QoL/health status. There are no RCTs of NIV versus IMV in AHRF and the recommendations regarding NIV for AECOPD remain appropriate. Hypoxaemia is often more severe than in AECOPD, in some, relating to co-existent pulmonary hypertension. Secretion clearance is also a major issue and may render NIV ineffective or poorly tolerated.204–207 Case series of patients with CF receiving NIV as a bridge to transplantation have been reported.208 209

As the outcome of invasive ventilation in CF is generally poor, it has been recommended that NIV be used preferentially.202 In a retrospective multicentre study of 60 ICU hospitalisations for 42 adult patients with CF admitted between 2000 and 2003, NIV was used in 57% and was successful in 67% of these.210 Endotracheal intubation was implemented on 19 occasions and ICU mortality was 14%. Among recognised markers of CF disease severity, only the annual FEV1 loss significantly related to outcome (HR=1.47, p=0.001). Admission SAPS II, a pathophysiological score, weakly predicted outcome (HR=1.08, p<0.001), but the perceived need for endotracheal intubation strongly predicted mortality (HR=16.60, p<0.001). In a study from a single centre, 30 patients were managed by IMV on 34 occasions.211 Eleven patients died in the ICU and a further seven before hospital discharge. Sixty per cent intubated for pneumothorax and/or haemoptysis survived contrasted, with only 30% when intubated for infection. Mean survival post-discharge was 447 days. There were no significant differences in survivors for colonising organism, frequency of infectious exacerbations or acute severity of illness. A greater fall in BMI over the preceding 24 months was more frequent in non-survivors. The authors concluded that patients with CF developing AHRF due to haemoptysis and/or pneumothorax should be considered for management by IMV.

Evidence statements

Chronic disease markers are more relevant than rates of hospitalisation or FEV1 decline in assessing outcome in AHRF complicating CF (Level 2+).

When ventilatory support is needed, outcome following IMV is worse than with NIV, especially when infection is the precipitant (Level 2+).

Secretion clearance is a major issue and may render NIV ineffective or poorly tolerated (Level 2–).

Recommendations

45. In patients with CF, controlled oxygen therapy should be used in AHRF (Grade D).
46. In patients with CF, NIV is the treatment of choice when ventilatory support is needed (Grade C).
47. In patients with CF, specialised physiotherapy is needed to aid sputum clearance (Grade D).
48. In patients with CF, a mini-tracheostomy combined with NIV may offer greater chance of survival than resorting to IMV (Grade D).

Restrictive lung disease

The causes of AHRF include severe chest wall deformity, neuromuscular conditions that affect the respiratory muscles and OHS. Presentation is often with advanced chronic hypercapnia. An insidious decline in health may not have been medically recognised as being due to the development of respiratory failure. Acute presentations, often with infection precipitating acute illness, are likely when the VC is <1 L. Unlike AECOPD, recurrent critical episodes do not preclude intervening good life quality, acceptable health status and prolonged survival. There are no RCTs to guide practice in AHRF and the recommendations presented are extrapolated from the AECOPD literature, from reports of the value of domiciliary NIV (most evidence coming from trials in the more progressive NMDs) and from expert opinion.

NMD and CWD

Respiratory impairment generally parallels disease progression in NMD. However, in some, diaphragm involvement precedes locomotor disability and presentation with acute on chronic hypercapnia is typical. This pattern is characteristic of acid maltase deficiency and the amyotrophic lateral sclerosis variety of motor neurone disease. In some of the muscular dystrophies, bulbar muscle involvement is common. As a result, sleep disordered breathing may arise from a combination of respiratory muscle weakness and upper airway obstruction. The resulting nocturnal hypoventilation will then gradually spill over into daytime hypercapnia. Bulbar dysfunction also renders voluntary cough less effective. NICE had previously published guidance on the use of NIV in motor neurone disease,212 which did not consider management of acute illness nor the value of intubation if NIV fails. New guidance from NICE on motor neurone disease is in preparation. While respiratory failure is predictable in the majority, some MND patients present before a formal diagnosis has been made.213 214 This also occurs in less progressive conditions such as Limb Girdle muscular dystrophy or Myotonic Dystrophy. Without domiciliary NIV, the natural history of neuromuscular and CWDs is of progressive chronic hypercapnic failure leading to death. It is well recognised such individuals can survive long term on home NIV with a good QoL, even if they present initially in severe respiratory failure. Thus individuals with NMD and CWD who present with AHRF should not be denied acute NIV. The success of domiciliary NIV has made the management of any associated cardiomyopathy increasingly clinically relevant.

In CWD, evidence of pre-existing sleep disordered breathing is also common at AHRF presentation. In some, marked chronic hypercapnia is an unexpected finding when ABGs are
performed. Such patients may have established pulmonary hypertension, chronic hypoxaemia and polycythaemia.

In contrast to AECOPD, where the degree of acidosis is more important than the degree of hypercapnia, any elevation of pCO₂ in NMD/CWD may herald an impending crisis. Patients have a reduced respiratory reserve but may initially sustain sufficient alveolar ventilation to maintain normal carbon dioxide tension. Minor infection, such as coryza, may be provocative and over the next 24–72 h progressive hypercapnia may develop. Tolerance of acute and chronic hypercapnia varies considerably. Some patients are excessively sleepy with minimal elevation of pCO₂, while others remain alert despite much more severe hypercapnia. NIV should be considered in any breathless/acute unwell patient with NMD/CWD before respiratory acidosis develops.

In the absence of bulbar dysfunction, NIV is usually well tolerated in the restrictive causes of AHRF. Unless there is significant skeletal deformity, a low degree of PS (eg, a pressure difference of 8–12 cm) is needed in NMD. By contrast, in severe kyphoscoliosis, an IPAP >20, and sometimes up to 30, may be required because of the high impedance to inflation. Expiratory flow is normally not limited in either restrictive category and the inspiratory/expiratory ratio (IE) for the backup rate (or PCV) should initially be set at 1:1 to allow an adequate time for inspiration. Bulbar dysfunction renders effective NIV more difficult to achieve, requires a higher EPAP to overcome upper airway obstruction and needs special attention to aid cough and the clearing of upper and lower airways. Clinical experience in providing NIV is needed to best titrate the EPAP. A modest increase in the domiciliary ventilator settings is advised in the case of home mechanical ventilation patients being admitted with AHRF.

While triggering is usually normal in CWD, it is commonly inadequate in the other restrictive conditions. Many patients with NMD find PCV more comfortable and this may also more effectively control nocturnal hypoventilation.

Evidence statement

There are no trials comparing NIV with IMV in AHRF in NMD or CWD. Domiciliary NIV is effective in treating chronic hypercapnia, improves long-term survival and preserves a good or acceptable QoL (Level 4).

Recommendations

49. Controlled oxygen therapy should be used in patients with NMD or CWD and AHFR (Grade D).

50. NIV should almost always be trialled in the acutely unwell patient with NMD or CWD with hypercapnia. Do not wait for acidosis to develop (Grade D).

51. In patients with NMD or CWD, NIV should be considered in acute illness when VC is known to be <1 L and RR >20, even if normocapnic (Grade D).

52. In patients with NMD or CWD, consider controlled ventilation as triggering may be ineffective (Grade D).

53. In NMD and CWD, unless escalation to IMV is not desired by the patient or is deemed to be inappropriate, intubation should not be delayed if NIV is failing (Grade D).

Good practice points

- In patients with NMD or CWD, senior/experienced input is needed in care planning and is essential if differences in opinion exist or develop between medical staff and patient representatives.

- In patients with NMD, it should be anticipated that bulbar dysfunction and communication difficulties, if present, will make NIV delivery difficult and may make it impossible.

- Discussion about NIV and IMV, and patients’ wishes with respect to cardiopulmonary resuscitation, should occur as part of routine care in patients with NMD or CWD.

- In patients with NMD or CWD, nocturnal NIV should usually be continued following an episode of AHRF pending discussion with a home ventilation service.

NIV failure and discontinuing NIV following recovery in NMD and CWD

Decisions regarding resuscitation and intubation can be particularly challenging as little or no evidence exists for most of the causative conditions, communication with the patient may be difficult and/or cognition be impaired and there may be unreasonable expectation on the part of families and carers. A resuscitation plan is important but may be difficult to negotiate. Inability to clear secretions is a common cause of NIV failure. This may result from an excessive volume of secretions or from a combination of limited inspiratory capacity, expiratory muscle weakness and bulbar dysfunction. Specialist advice and experience is required to manage NIV in the presence of bulbar dysfunction and to provide effective cough assistance. As with all patients, good communication is important. As this may be a challenge, it is another reason for seeking specialist help and advice. Enlisting the help of normal carers may be useful because they may engender more reassurance to patients and be better at aiding sputum clearance.

Recovery usually takes longer than in AECOPD, so that stepping down the time on NIV should proceed more slowly, and NIV will need to be continued overnight. The higher the presentation HCO₃⁻, the longer the period of relative hyperventilation required to reduce buffering capacity. A target pCO₂ around 6.5 kPa self ventilating is recommended. Following recovery, the majority of individuals with NMD or CWD will require NIV at home. NIV should continue overnight until discussion with a home ventilation service.

Good practice points

- In patients with NMD or CWD, intolerance of the mask and severe dysphonia are less likely to cause NIV failure. Bulbar dysfunction makes NIV failure more likely.

- Deterioration in patients with NMD or CWD may be very sudden. Difficulty achieving adequate oxygenation or rapid desaturation during a break from NIV are important warning signs.

- In patients with NMD or CWD, the presence of bulbar dysfunction, more profound hypoxaemia or rapid desaturation during NIV breaks suggests that placement in HDU/ICU is indicated.

IMV in NMD/CWD

Many clinicians have limited experience of managing NMD and CWD. There is the danger of underestimating survival potential in the face of severe general disability. Patient choice and seeking the views of advocates when communication with the patient is difficult are paramount. Discussion with a specialist centre on both the delivery of IMV and weaning is recommended.

The risk of sudden deterioration is greater due to reduced respiratory reserve, impaired cough, cardiomyopathy (possibly undiagnosed) and sometimes communication challenges. Intubation practice, elective or in AHRF, varies between centres
and between countries. For instance, in motor neurone disease (MND), elective intubation is reported to occur in 0.8% (Ireland), 6% (USA) and 10.6% (Italy) of cases.214

Outcome data following IMV are limited to case series in MND and OHS. These reports usefully illustrate shared issues in progressive NMD and many patients with advanced CWD. One report of outcome in MND following intubation for AHRF highlighted that 50% of patients were undiagnosed at the time of intubation, only 17% weaned and few left hospital.216 Recently, Sancho et al217 reported a median survival of 1 year in patients intubated after failing acute NIV. Chio et al218 reported on 1260 MND cases, over an 8-year period, from a single Italian neurology centre; 134 patients received IMV, which was initiated as an emergency in 40%. Median survival was 250 days. Death occurred in hospital in 20%, at home in 48% and in a nursing home in 32%. Neither patient experience nor economic analysis was reported.

The outcome of patients with MND referred to a specialist weaning service in the UK was examined by Chadwick et al.218 Thirty patients had been transferred over a 15-year period. Diagnosis followed intubation in 17. In 14 patients, extubation to long-term NIV was possible, of whom 9 were non-bulbar cases and 10 returned home. Thirteen remained tracheostomy ventilated, of whom 9 were bulbar and 7 returned home. Median survival from tracheal intubation was 13.7 months (95% CI 0 to 30.8) for those known to have MND and 7.2 months (95% CI 5.1 to 9.4) for those not previously diagnosed.

There has been a call for the value of IMV in MND to be re-evaluated both as an elective policy and at the time of crisis.219 In many of the other NMDs, for example, acid maltase deficiency and Duchene Muscular Dystrophy, a more prolonged survival rate with a good QoL is to be expected following recovery from AHRF, and an aggressive approach to managing it is, in the opinion of the guideline group, more justified than has historically been the case in the UK. It is also what most patients and their families want. Expert experience is that the majority of patients will survive a period of IMV. Comorbidity, especially associated cardiomyopathy, is important prognostically. The weaning process is often prolonged but, in the absence of severe bulbar dysfunction, many can be safely extubated onto NIV and avoid a tracheostomy. Should this fail, and a tracheostomy be required, specialist centre experience is that subsequent decannulation is possible in most. While long-term survival may be limited, QoL may be acceptable and health status may improve with domiciliary NIV. This is particularly the case in the more slowly progressive NM conditions and in stable CWD. In the latter group, even advanced pulmonary hypertension may resolve.

Evidence statements
There are national (and centre) differences in use of IMV in AHOF complicating motor neurone disease (Level 3). The diagnosis of motor neurone disease, and other neuromuscular conditions, is sometimes only made after admission to the ICU for IMV (Level 3). Decannulation of a tracheostomy is more difficult when there is bulbar disease (Level 3).

Planned elective domiciliary NIV is preferable to crisis management in NMD and CWD. This reduces the risk of acute presentation and provides a proven alternative to IMV which risks prolonged or permanent tracheostomy ventilation (Level 3).

Recommendations
54. In patients with NMD or CWD, senior staff should be involved in decision-making, in conjunction with home mechanical ventilation specialists, if experience is limited, and especially when the appropriateness of IMV is questioned (Grade D).

55. Advance care planning, particularly around the potential future use of IMV is recommended in patients with progressive NMD or CWD. This may best be supported by elective referral to a home ventilation service (Grade D).

IMV strategy in MND and CWD
In patients with MND without significant chest wall distortion, the impedance to inflation is low. It is rarely necessary to use an IPAP above 20. It should initially be set at 10 and increased according to the resulting tidal volume. In contrast, patients with kyphoscoliosis usually require high inflation pressures. Expiration is generally not flow limited but impedance is typically high so that an l:E ratio of 1 to 1 is recommended in both diagnostic groups.

When lung volume is reduced, there is radiological evidence of lobar collapse or unexplained hypoxia, the PEEP setting on the ventilator may need to be increased up to or above 10 cm.14 15 Adjustments should be individualised according to ventilatory parameters (RR, dynamic compliance, plateau pressure) and patient comfort.

Good practice points
- Patients with NMD usually require low levels of PS.
- Patients with chest wall deformity usually require higher levels of PS.
- PEEP in the range 5–10 is commonly required to increase residual volume and reduce oxygen dependency in both patient groups.

Obesity hypventilation syndrome
In obese patients, hospitalised for any reason, the presence of hypercapnia increases morbidity and mortality.220 Despite this, currently, there is a lack of evidence to guide treatment of either chronic hypercapnia or AHRF complicating obesity. One non-randomised trial suggested that long-term survival is better in those who accept treatment for sleep disordered breathing compared with those who do not.221 Severe OSA is the principal cause of hypercapnia, but hypoventilation also results from the mechanical effect of obesity.222

Presentation with acute on chronic respiratory failure is more common than de novo AHRF but the precipitant cause for destabilisation may be unclear. Not uncommonly, chronic hypercapnia is unexpectedly revealed peri-operatively following routine or emergency surgery in an obese patient not known to have OHS. The possibility of OSA/OHS in the morbidly obese (BMI >35) needs to be borne in mind by surgical and anaesthetic teams.

In the absence of evidence, we recommend that the indications for NIV in the breathless obese patient should be the same as in AECOPD ie pCO2 >6.5 and pH <7.35. Additionally, NIV should be considered in any patient admitted to hospital with a raised pCO2 who is excessively somnolent or when there is evidence of fluid retention. Following recovery, patients will need to be referred to an HMV centre. Patients with OHS can sometimes be switched to CPAP at a later date.

Evidence statements
In patients with OHS, NIV is indicated if there is respiratory acidosis using the same criteria as in AECOPD (Level 1–). In the absence of acidosis, NIV may be indicated in some hypcapnic and/or somnolent obese patients (Level 2+).

Recommendations
56. Controlled oxygen therapy should be used in patients with OHS and AHRF (Grade D).
57. In patients with OHS, NIV should be started in AHRF, using the same criteria as in AECOPD (Grade B).
58. NIV is indicated in some hospitalised obese hypercapnic patients with daytime somnolence, sleep disordered breathing and/or right heart failure in the absence of acidosis (Grade D).

NIV settings and placement in OHS

Obese patients with severe AHRF have a significant risk, despite receiving NIV, of sudden deterioration and are likely to be difficult to intubate (see below). Upper airway obstruction is common and will be more apparent during sleep. It may persist, despite increasing the EPAP as indicated by intermittent abdominothoracic paradox during NIV ‘assisted’ breaths. Another clue is intermittent mask leak that accompanies obstructed inspiration. A more upright position may help, but an EPAP in the 10–15 range is often required. Expert assessment is recommended to titrate the EPAP. Tidal volume may be compromised by high level EPAP and, in some, the impedance to inflation is very high and an IPAP of >30 is required.217 Prolonging Ti will increase the resulting Vt delivered so a I:E ratio of 1:1 is advised. If the resulting Vt is still inadequate, consideration should be given to using volume-controlled ventilation or a volume-assured mode,92 although the benefits of the latter are currently unproven. Different EPAP settings may be appropriate depending on sleep/awake state.

Good practice points

- High IPAP and EPAP settings are commonly required in patients with OHS (eg, IPAP >30, EPAP >8).
- Volume control (or volume assured) modes of providing NIV may be more effective when high inflation pressures are required.

NIV failure in OHS

In patients with OHS, the same indicators suggest a failing patient and the same troubleshooting solutions apply as in AECOPD (see table 3). Fluid retention is common and its extent is commonly under-estimated. It may be in excess of 20 L. Achieving an SaO2 88–92% may be difficult and relates to collapse of dependent lung and/or reflects underlying pulmonary vascular disease. Sudden and precipitous falls in oxygenation may follow temporary removal of NIV. If high EPAP settings fail to improve the A-a gradient, a ventilator offering oxygen blending may be required. Difficulty in clearing secretions may contribute to poor gas exchange.

Good practice points

- Fluid overload commonly contributes to ventilatory failure in patients with OHS and its degree is easily underestimated.
- Forced diuresis may be useful.
- As the risk of NIV failure is greater, and intubation may be more difficult, placement in HDU/ICU for NIV is recommended.

Discontinuing NIV in OHS

During wakefulness, weaning of NIV should proceed as in AECOPD. NIV overnight should be continued pending discussion with the local home ventilation service. Other aspects, such as consideration of bariatric surgery and optimal EPAP settings when returning home, are important aspects of continuing care.

Good practice points

- NIV can be discontinued as in patients with AECOPD.
- Many patients with AHRF secondary to OHS will require long-term domiciliary support (CPAP or NIV).
- Following an episode of AHRF, referral to a home ventilation service is recommended.

IMV strategy in OHS

Intubation can be challenging and patient deterioration may be rapid. There is also a higher risk of aspiration. Pressure control is recommended until stability has been achieved and should be initially set at 20 and increased according to the resulting tidal volume. Inspiratory pressure in excess of 30 cm H2O may be required. To recruit collapsed lung, PEEP may need to be 10–15 cm.14 15 It should be adjusted according to ventilatory parameters (RR, dynamic compliance, plateau pressure) and patient comfort.

Good practice points

- In patients with OHS, pressure-controlled MV is recommended initially.
- In patients with OHS, high PEEP settings may be needed to recruit collapsed lung units and correct hypoxemia.
- In patients with OHS, forced diuresis is often indicated.

WEANING FROM IMV

Introduction

Weaning is defined as the progressive reduction of ventilatory support leading up to extubation. Delayed weaning complicates 6% of patients managed by IMV but consumes 37% of ICU resources.227 In one study, up to 50% of patients who self-extubated did not require re-intubation,224 implying that many patients are treated with IMV for longer than necessary. Clinical criteria to be met before starting weaning are detailed below:225 226

- Adequate oxygenation: PaO2/FiO2 ratio >27 kPa (200 mm Hg)
- FiO2 <0.5
- PEEP <10 cm H2O
- Adequate alveolar ventilation (pH >7.3, pCO2 <6.5 kPa).

Fluid balance should also be optimised. The detrimental effect of excess hydration is now recognised in sepsis227 and in acute lung228 and kidney injury.229 A positive fluid balance adversely affects alveolar ventilation, oxygenation, weaning progress and extubation outcome.224 230 Brain Natriuretic Peptide (BNP) has been reported to predict failure to wean and correlates with weaning duration; a BNP-directed fluid management strategy has been reported to shorten time to extubation, particularly in patients with left ventricular dysfunction.231

Evidence statements

Easily measured clinical parameters indicate when weaning can start (Level 2+).

Excess fluid administration may delay weaning or contribute to its failure (Level 2+).

In left ventricular dysfunction, a BNP-directed fluid management strategy has been shown to shorten the duration of IMV (Level 2).

Recommendations

59. Treating the precipitant cause of AHRF, normalising pH, correcting chronic hypercapnia and addressing fluid overload should all occur before starting weaning (Grade D).

60. A BNP-directed fluid management strategy should be considered in patients with known left ventricular dysfunction (Grade B).

Weaning methods

Despite several multinational studies, there is no consensus as to the optimal weaning method. Brochard et al232 reported that progressively reducing PS was better than other weaning methods. Subsequent trials have reported that daily (or multiple) T piece trials (SBTs) are as effective as PS weaning.233 234 It is likely that patient-specific characteristics are more important than the weaning protocol in determining the duration of...
weaning. There is agreement that the Synchronised Intermittent Mandatory Ventilation method is inferior to PS and T piece weaning. It is also accepted that a formalised weaning plan, and staff familiarity with the approach adopted on the ICU, are important factors to improve successful weaning.235

Evidence statement
Progressive reduction of PS and daily SBTs are satisfactory methods of weaning (Level 1+).

Recommendations
61. Assessment of the readiness for weaning should be undertaken daily (Grade B).
62. A switch from controlled to assisted IMV should be made as soon as the patient recovery allows (Grade C).
63. IMV patients should have a documented weaning plan (Grade B).

Assessing readiness for discontinuation of mechanical ventilation

SBTs are used to assess readiness to resume normal breathing. During the SBT, a patient breathes with minimal or no PS (defined as <8). A successful trial requires the absence of respiratory distress. Failure of an SBT may be defined by subjective (comfort) or objective (deterioration in gas exchange or measured ventilator parameters) criteria.232-233 Studies have shown that the majority of SBT failures occur within 30 min.236-237 Repeated failure of SBT should lead to consideration of other methods of weaning.238-239

It is important to note that the criteria that define success of an SBT do not necessarily reflect the likelihood of successful extubation. About 10% of patients who successfully managed an SBT will fail to maintain adequate gas exchange and/or develop signs of distress following extubation.240 An SBT assesses the balance of respiratory load to capacity of the respiratory muscles but does not take into account other factors that may affect success such as upper airway patency, bulbar function, sputum load or effectiveness of cough.240

Evidence statement
A SBT is useful in assessing load/capacity but does not predict the success of extubation (Level 1+).

Recommendation
64. A 30 min SBT should be used to assess suitability for extubation (Grade B).
65. Factors including upper airway patency, bulbar function, sputum load and cough effectiveness should be considered prior to attempted extubation (Grade D).

Outcome following extubation

Successful extubation is defined as the absence of the need for ventilatory support for 48 h. Patients receiving post-extubation NIV (see below) are classified as ‘weaning in progress’.241

Much of the evidence regarding the prediction of the risk of post-extubation failure has come from trials of relatively short duration IMV and with a mixture of underlying pathologies.235-242 Several risk factors have been identified. The more adverse factors present, the greater the risk of extubation failure. Risk factors for extubation failure are shown in box 2.235-242

Respiratory distress may occur early or develop later on after extubation. Early failure commonly results from loss of airway patency, for example, from upper airway oedema that becomes evident following removal of the endotracheal tube.244 Patients with NMD are at risk of early extubation failure due to bulbar dysfunction and/or ineffective cough despite a successful SBT. The planned use of NIV and an MI-E following extubation reduces the risk of early failure. Late extubation failure is more complex in aetiology and more than one cause may be present. The causes are summarised below:244

- Capacity–load imbalance: patients with severe airflow obstruction or neuromuscular weakness;
- Impaired bulbar function: aspiration of upper airway secretions, impaired gas exchange and/or obstructed breathing;
- Ineffective cough: typically in NMD/CWD but also in other patients with AHRF;
- Non-respiratory issues—myocardial ischaemia/left ventricular dysfunction, encephalopathy/delirium or severe abdominal distension.

Evidence statement
Patient, clinical and ventilatory factors aid the identification of patients at increased risk of extubation failure (Level 2+).

Recommendation
66. Care is needed to identify factors that increase the risk of extubation failure so that additional support, such as NIV or cough assist, can be provided (Grade B).

Weaning protocols

Weaning protocols that specify the steps to follow during weaning have been claimed to reduce the duration of IMV, increase the success of extubation, reduce unplanned or accidental extubation and reduce the tracheostomy rate, ventilator-associated complications and costs, compared with usual care.245 The studies summarised in this review were, however, not specific to AHRF. Most were performed in the USA, where differences in supervision of patient management exist compared with the UK. There is also marked variation in the weaning methods and protocols between the studies reported. A European study reported that a weaning protocol did not reduce ventilation time.246 Computer-automated weaning, in which adjustment in pressure settings occurs in response to changes in patient parameters, has been compared to professional-led weaning. One multicentre RCT found that duration of weaning was reduced.247 A second study reported no difference in weaning duration between automated weaning and weaning by an experienced nurse.248 There is currently insufficient evidence to support the use of automated weaning over clinical/nurse-led protocols.

Evidence statements
Weaning protocols may reduce the duration of IMV and ventilator associated pneumonia (Level 1+).

There is conflicting evidence regarding the value of computer-automated weaning (Level 1–).

Box 2 Risk factors for extubation failure following invasive mechanical ventilation (IMV)

- Positive fluid balance
- Raised rapid shallow breathing index during spontaneous breathing trial
- Pneumonia or pulmonary disease as the cause requiring IMV
- Increased age
- Prolonged duration of IMV
- Anaemia
- Increased severity of illness
- Low albumin
- Previous failed extubation
- Bulbar dysfunction
**Recommendations**

67. Although an organised and systematic approach to weaning is desirable, protocols should be used with caution in patients with AHFRF (Grade B).

68. The use of computerised weaning cannot be recommended in AHFRF (Grade D).

**Use of NIV in the ICU**

Planned NIV to speed weaning from IMV

In an uncontrolled study on lung transplantation, NIV was found to speed extubation and reduce the time spent invasively ventilated and the attendant complications. Subsequent studies have compared the use of NIV with conventional weaning in patients who have failed an SBT. Benefit was demonstrated in patients with underlying COPD. These studies utilised NIV at high levels of PS and for longer than 24 h. NIV weaning was reported to confer no benefit in a subsequent study. A subsequent Cochrane review concluded that the use of NIV to speed weaning in patients with COPD reduced mortality and the incidence of pneumonia without increasing the need for re-intubation.

**Evidence statements**

NIV has been shown to accelerate weaning from IMV in the patient with COPD failing an SBT (Level 1+).

**Recommendation**

69. NIV is recommended to aid weaning from IMV in patients with AHFRF secondary to COPD (Grade B).

70. In other causes of AHFRF, NIV may have a role in shortening the duration of IMV when local expertise in its use exists (and of cough assist when indicated) and there are features present that indicate extubation is likely to be successful (Grade D).

NIV in high-risk patients

NIV has been assessed in patients who have passed an SBT but who have risk factors for extubation failure such as age >65 years, poor cough, cardiac and respiratory comorbidity, and hypercapnia (while ventilated and/or pre-existing). NIV was reported to reduce the re-intubation rate and mortality in one study, and has been reported to be effective where obesity (BMI >35 kg/m²) is an additional adverse feature.

**Evidence statements**

NIV may be effective in reducing respiratory failure, re-intubation and mortality in COPD (Level 1+) and patients with increased BMI (Level 2+).

Planned post-extubation NIV reduces mortality, ICU and hospital length of stay and the incidence of ventilator-associated pneumonia (Level 1+).

**Recommendation**

71. Prophylactic use of NIV should be considered to provide post-extubation support in patients with identified risk factors for extubation failure (Grade B).

NIV as ‘rescue’ therapy post-extubation

A number of RCTs have examined the use of NIV as an unplanned ‘rescue’ treatment for post-extubation respiratory distress. One multicentre RCT reported that patients who passed an SBT but who then developed post-extubation respiratory failure had an increased ICU mortality rate if treated with NIV as opposed to re-intubation. This study has been criticised as few patients were treated in each participating centre, despite a long recruitment period, raising the suspicion that lack of familiarity with NIV may have resulted in it being poorly applied. The patients who failed NIV and went on to require intubation also received long periods of ineffective NIV before re-intubation, 9 h longer than the control group. This may have contributed to the worse outcome. Post hoc analysis suggested a benefit with NIV post-extubation in patients with COPD.

**Evidence statement**

The use of NIV as rescue therapy for unexpected post-extubation respiratory failure does not improve outcome and may be detrimental (Level 1+).

**Recommendation**

72. NIV should not be used routinely for unexpected post-extubation respiratory failure (Grade B).

73. In COPD, a trial of NIV may be justified for unexpected post-extubation respiratory failure where local expertise exists (Grade D).

**CARE PLANNING AND DELIVERY OF CARE**

**Appropriate care environments for the delivery of NIV**

A study by Roessler and colleagues from Germany randomised 51 patients to either out-of-hospital NIV or standard medical treatment. Out-of-hospital NIV was reported to be feasible, safe and effective. A survey of French mobile ICUs also suggests that NIV and CPAP can be safely employed pre-hospital in acute cardiogenic pulmonary oedema but not in other causes of respiratory failure. Further evaluation of out-of-hospital NIV in AHFRF is required.

NIV is commonly initiated in the ED, but given the other priorities and pressures on emergency resuscitation areas patients should be transferred as soon as practicable to an environment appropriately staffed and equipped to provide on going care. A prospective observational study of 245 patients attending 24 hospital EDs in Australia identified the staff responsible for NIV set-up. This was equally distributed between nursing and medical personnel. Hess et al conducted a survey of 132 academic EDs in the USA, and concluded that, although NIV was widely available, physician confidence/competence was a barrier to optimal application. A survey of NIV use in UK EDs found a wide variety of practice and suggested the need for a specific ED guide for NIV. A pro forma-based COPD management tool, supported by targeted education, was reported to improve ED care including the use of NIV.

Previous guidelines have recommended limiting the number of areas providing NIV to ensure that staff perform it sufficiently regularly. Suitable sites need to be able to provide an NIV service 24/7 and integration with critical care services is essential. If NIV is provided in more than one area within a hospital, protocols and guidelines should be shared. Current NICE Quality Standards for COPD include guidance on how to benchmark NIV provision. The requirements for an NIV service are summarised in box 3.

For all but the mildest cases, Nava and Hill recommend that NIV be delivered in a level 2 facility with enhanced staffing levels. A survey carried out in 1999 found that NIV was provided in level 2/3 facilities in most western European countries. In contrast, NIV has been delivered in admission or respiratory ward settings in the UK. This may partially account for the poor performance and high mortality rates associated with use of NIV reported by audits. The 2009 ICS recommendations reiterate level 2 as the appropriate clinical environment for NIV and the 2008 joint BTS, ICS and RCP guide on the use of NIV in COPD with AHFRF recommends one nurse for every 2 NIV cases, especially during the first 24 h of treatment.

Despite this, in the 2013 BTS NIV audit, 91% of patients were treated on general medical wards despite 43% having pH<7.25. This was associated with a low intubation rate and
excess mortality. Although the care plan in 21% of cases included IMV should NIV fail, only 3% were intubated (versus an expected rate of 7%). Overall, the audit found that mortality in the AECOPD group was 28% if NIV was delivered in HDU/ICU and 40% if not. With a median pH of 7.24 for the whole patient population (2693 cases), this suggests that some were not being treated for lesser degrees of acidosis, where NIV success is more guaranteed, and that those receiving NIV were not placed in the appropriate care environment given the severity of acidosis.

A number of strategies have been explored to support the effective use of NIV outside the HDU/ICU. Sala et al. described the practicalities of creating a respiratory intermediate care unit. Paus-Jenssen et al., in a Canadian prospective study, used an expert respiratory therapist team to implement NIV across a number of clinical environments. In a similar study, critical care outreach nurses supported NIV delivery elsewhere in the hospital. As a result, mortality was reduced from 57% to 35%. A greater number of patients were also identified as suitable for IMV when failing NIV. Some of the challenges of care delivery in this field are highlighted in the National COPD Audit Programme 2014 findings on resources and organisation of care in acute National Health Service (NHS) units, where only 30% of outreach programmes operated out of hours during weekdays and 59% of respiratory wards reported no level 2 capability. Cabrini reported an Italian prospective study of NIV administered in a non-ICU setting but managed by an anaesthetist-led medical team. In 129 consecutive treatments, 10% required intubation and there was a low mortality rate of 12.4%. These reports together suggest that collaboration between admitting teams and the ICU can improve the delivery of care in AHRF.

Hospitalisation with AHRF involves 3 phases—immediate clinical assessment, an assisted ventilation plan when appropriate and the formulation of a future care plan (short term in the event of NIV failure and long term on recovery and discharge or, depending on progress, the provision of end of life care). Figure 3 details key elements and box 4 provides a discharge checklist.

It has been estimated that an average-sized district general hospital, serving a population of 250 000, should anticipate, depending on local COPD prevalence, up to 100 AECOPD cases requiring ventilatory support per annum. Given the additional causes of AHRF, this probably equates to 150 NIV/IMV cases in most hospitals, and considerably more in areas with high COPD and/or OHS prevalence or those hospitals serving larger populations. NIV facilities should be able to cope with seasonal variation and the increased demand that may occur during influenza epidemics.271

Box 3 Essential requirements for an NIV service

- Specifically identified area(s) for NIV treatment at level 2 equivalence.
- Staffing levels above that of a general medical ward with one nurse for every 2 NIV cases (especially during the first 24 h of treatment)
- Locally developed NIV protocols (based on published best practice guides) uniformly applied across all areas
- A designated lead with a ‘core’ multidisciplinary group (physicians, nurses, physiotherapists) co-ordinating NIV service provision and linked with critical care services
- Access to expert support for NIV technical advice in and out of hours
- Mechanisms for regular audit
- Regular staff educational updates and training module for new staff

Immediate Clinical Assessment

Oxygenation target 88-92%
Acid—Base Status?
Evidence of other organ dysfunction?
Co-morbidities?

Administer steroids, bronchodilators, antibiotics as indicated and get specialist therapy help for NIV/OHS patients.

Assisted Ventilation Plan

Options:
- Intubation and transfer to ICU for IMV
- NIV with transfer to ICU as risk of requiring IMV
- NIV before/after transfer to NIV unit
- NIV before/after transfer to acute ward with specialist support
- Non implementation or discontinuation of assisted ventilation

Review patient and family wishes
Ensure NIV experienced clinical input and assistance of ICU if needed
Use locally agreed protocols for AHRF management
Ensure frequent review of progress and agreed avenues for escalation or de-escalation
Document care plans and audit outcomes

Recovery and discharge phase

Review reasons/route of admission and consider methods to improve if these were problematic
Discuss future care planning with patient/family and inform community services of the result of such discussion
Arrange early specialist review, pulmonary rehabilitation & help with smoking cessation as indicated
Provide warning card/inform ambulance services re future need for controlled oxygen therapy
Consider referral to home NIV service eg NMV cases or suspected sleep disordered breathing
Learn from any identified mistakes through multi professional review.

Figure 3 The three phases of patient management in acute hypercapnic respiratory failure.
As discussed in the Management section, patient outcomes reported in UK national audits are notably worse than would be expected from trial data and facilities for provision of NIV and evidence of consultation with the ICU, are frequently limited or inadequate. Important deficiencies that have been identified include delays in commencing ventilatory support, under-recognition of more complex acid–base disturbances, use of inadequate ventilatory pressures, rare use of a different mask when NIV is failing, lack of progression from NIV to IMV and lack of consultation in decision-making. The preponderance for application of NIV in lower level facilities than elsewhere in the world (outlined above) along with evidence of a lack of integration with the ICU, indicates that attention directed at organisational factors are needed and are highly likely to improve patient outcome and experience in AHRF.

NIV facilities need to encompass adequate capacity, and the expertise and associated staffing levels, to deal with complex critically ill patients who have a significant risk of death. To be effective, the NIV service needs to have good operational links to the ICU in the expectation that 10% to 20% of NIV-treated patients should be managed in HDU/ICU and that many will be potential candidates for IMV. The case for a specifically identified and appropriately staffed and equipped area for providing NIV is strongly supported by the evidence. In some European countries, NIV services are provided in a Respiratory Intermediate Care Unit.

**Evidence statements**

A care environment with either level 2 or 3 staffing favours a successful outcome from NIV therapy (Level 2+). Coordination between the ICU and ward areas improves outcome in AHRF (Level 3). Organisational aspects are pivotal in achieving best outcomes (Level 4).

**Recommendations**

74. NIV services should operate under a single clinical lead with formal working links with the ICU (Grade D).
75. The severity of AHRF, and evidence of other organ dysfunction, should influence the choice of care environment (Grade C).
76. NIV should take place in a clinical environment with enhanced nursing and monitoring facilities beyond those of a general medical ward (Grade C).

**Good practice points**

- A 2–4 bedded designated NIV unit (located within a medical high dependency area or within a respiratory ward with enhanced staffing levels) provides a robust basis for the provision of NIV in a DGH serving a population of 250 000 and with an average prevalence of COPD.
- Areas providing NIV should have a process for audit and interdisciplinary communication.

**Palliative care and advanced care planning**

It is recognised that palliative interventions may be appropriate and yet be provided at the same time as therapies intended to prolong life. Accordingly, employing NIV as part of care that aims to relieve distress and has escalation limits may be entirely justified.

Effort is needed to establish patient preferences with respect to intubation or resuscitation status. Momen et al. in a systematic review of end-of-life conversations in COPD, found considerable variation among patients in the desire to discuss end of life. Almost 50% of patients did not wish to have such a conversation and there was a preference to wait until the disease was ‘advanced’, with patient perception that this implied the last few days of life. Advance directives/living wills assist healthcare providers in tailoring clinical response and support. The importance of actively involving patient/family, especially regarding ‘do not attempt cardiopulmonary resuscitation’ (DNACPR) orders, are highlighted in revised recommendations following a judicial ruling. The essential element is that, while patients cannot insist on CPR being performed, the matter should be discussed. Perceived patient ‘distress’—which might be exacerbated by such discussion—is no longer regarded as sufficient grounds for not raising the issue. When the risk of causing physical or psychological harm is present, attempts should be made to talk to a healthcare advocate. The enormous challenges in this serve to emphasise the crucial nature of active and ongoing communication strategies. Chakrabarti reported interviews with 50 patients with stable COPD and found that discussion and demonstration of NIV equipment altered future treatment perceptions and willingness to consider an advance directive.

Sinuff et al. reported clinician attitudes to NIV in patients with acute respiratory failure and do not intubate/do not resuscitate instructions. While about 60% of physicians considered that NIV should be discussed in this context, 85% of respiratory therapists (those actually administering NIV) felt NIV should be actively promoted. This may reflect a lack of confidence and understanding, among physicians, of the potential for NIV to relieve distress and be effective even in advanced disease. In Denmark, 15% of patients with do not intubate instructions, and who received NIV, survived at least a year with COPD and congestive heart failure the most favourable underlying diagnoses.

**Evidence statements**

In advanced disease, care planning should ideally predate acute presentation or commence as early as possible on presentation with AHRF (Level 4).

Health professionals experienced in NIV delivery have a more positive view of the benefit of NIV and perceive patient treatment wishes more positively than do clinicians with less experience of NIV (Level 4).

---

Box 4 Discharge checklist after AHRF

- Arrange early specialist review, pulmonary rehabilitation and help with smoking cessation as indicated.
- Consider early home visit, for example, outreach COPD team/community nurses.
- Discuss future care planning with patient/family and inform community services of the result of such discussion.
- Provide warning card/inform ambulance services regarding future need for controlled oxygen therapy.
- Consider referral to home NIV service, for example, neuromuscular disease (NMD) cases or suspected sleep disordered breathing.
- Review reasons/route of admission and consider methods to improve if these were problematic.
- Learn from any identified mistakes through multiprofessional review.
Recommendations

78. Clinicians delivering NIV or IMV should have ready access to palliative medicine (Grade D).

79. Multidisciplinary advance care planning should be an integral part of the routine outpatient management of progressive or advanced disease and care plans should be reviewed on presentation during an episode of AHRF (Grade D).

80. The use of NIV may allow time to establish patient preference with regard to escalation to IMV (Grade D).

End-of-life care

A questionnaire study of 118 patients with COPD, carried out in Canadian teaching hospitals,279 reported that patients with COPD were less interested in prognostics, CPR, IMV or referral to palliative care than were patients with metastatic cancer. In another study, comparing QoL between patients with advanced COPD and patients with cancer, patients with COPD reported higher levels of physical discomfort with uncontrolled shortness of breath in 78%.280 A recent review of the 4 RCTs that have explored whether NIV relieves dyspnoea in AECOPD concluded that benefit was likely but that study limitations constrained a confident conclusion.281 With regard to physical symptoms, breathlessness and fatigue are dominant in AECOPD. Attention to secretion clearance is an additional major concern in bronchiectasis and CF and for many with NMD. Ability to communicate, to feel safe, to be individually respected and enabled to retain control are common psychological needs.

Patients receiving NIV as ‘ceiling care’, who fail to improve will need appropriate end-of-life attention, including appropriate sedation/relief of distress. It is important that if withdrawal of NIV is decided on, that this is achieved with minimum distress to the patient and their relatives. The BMA guidance on end-of-life care in 2007 did not address withdrawal of assisted ventilation.282 Although withholding and withdrawing are considered ethically equivalent,283 for many individuals, including clinicians, discontinuing mechanical ventilation is felt be emotionally different to, for instance, stopping haemodialysis. This may be because of the immediacy of the consequence.284 A Japanese study reported interviews with 35 critical care physicians and found withdrawing ventilation was regarded differently to stopping other life-sustaining measures because of concern over an abrupt and distressing demise.285 There was a desire for a ‘soft landing’, with a slow and gradual death perceived as ‘natural’. The ATS Clinical Policy Statement of 2007 provides comprehensive guidance on withdrawal of mechanical ventilation, including symptom management of the dying patient. It emphasises that decision-making is a process requiring frequent discussion with patient, family, health professionals and others.286 Pro-active family-centred conferences allow time for families to adjust and provision of literature on bereavement provides comprehensive guidance on withdrawal of mechanical ventilation or providing an alternative to mechanical ventilation in selected patients (such as those with COPD). There is little evidence of clear benefits to patients of ECO2R at present. In moderately hypoaxaemic ARDS, one RCT demonstrated that lower tidal volumes and ventilatory pressures could be achieved, but this failed to translate into a meaningful improvement in patient outcome.291 Larger studies are planned in the UK and Europe. In patients with COPD, there are no RCTs exploring the role of ECO2R. Twenty five potential candidates who had failed to improve with NIV were compared with historical controls treated in the same hospitals matched by the GenMatch process. Despite significant improvements in acidaemia and respiratory distress, the trial failed to show benefit in the primary outcome of need for intubation. The complication rate with ECO2R was high (52%) and this contributed to the need for intubation.292

The devices available for ECO2R have evolved over time. Early CO2 removal membranes were pumpless, required arterial and venous cannulation and used the patients own cardiac output to drive blood through the membrane. This resulted in significant shunting of cardiac output and the danger of limb ischaemia. An alternative approach is to take blood from a dual-lumen large bore cannula sited in a central vein and pump it through the membrane. The advantages of the veno-venous...
technique are principally lack of effect on cardiac output and reduced complications, particularly limb ischaemia. 

**Evidence statements**

Extra-corporeal CO₂ removal devices can reduce PaCO₂ and minute volume (Level 2—). Veno-venous extra-corporeal CO₂ removal in patients with AECOPD and an inadequate response to NIV has not been shown to reduce intubation rate and is associated with a 52% complication rate (Level 2—).

**Recommendations**

81. If local expertise exists, ECCO₂R might be considered:

- If, despite attempts to optimise IMV using lung protective strategies, severe hypercapnic acidosis (pH < 7.15) persists (Grade D);
- When ‘lung protective ventilation’ is needed but hypercapnia is contraindicated, for example, in patients with coexistent brain injury (Grade D);
- For IMV patients awaiting a lung transplant (Grade D).

**Good practice point**

ECCO₂R is an experimental therapy and should only be used by specialist intensive care teams trained in its use and where additional governance arrangements are in place or in the setting of a research trial.

**Helium/oxygen ventilation**

When mixed with oxygen (Heliox), the lower density of helium reduces resistance in the large airways where flow is predominately turbulent compared to air/oxygen ventilation. It therefore has a theoretical advantage in obstructive causes of AHRF. Heliox has been studied in combination with both NIV and IMV. It increases the delivered dose of bronchodilators and has been reported to improve symptoms and physiological variables in spontaneously breathing asthmatics. At oxygen concentrations >40%, Heliox has no benefit compared with oxygen–air mixtures. A large RCT in AECOPD found that Heliox in combination with NIV did not reduce rates of intubation, duration of ventilatory support or mortality. Heliox has been reported to reduce pCO₂ and airway pressures in intubated patients with severe asthma, but a subsequent meta-analysis concluded that it did not affect outcome. An uncontrolled study reported that Heliox improved patient comfort in the presence of post-extubation respiratory distress when stridor was present.

**Evidence statement**

The use of Heliox does not reduce rates of intubation and length of IMV, nor does it reduce mortality in patients of AECOPD or asthma (Level 1+).

**Recommendation**

82. Heliox should not be used routinely in the management of AHRF (Grade B).

**Author affiliations**

1British Thoracic Society, London, UK
2St James’s University Hospital, Leeds, UK
3Barts Health NHS Trust, London, UK
4Department of Respiratory Research, University Hospitals of Coventry and Warwickshire NHS Trust, Coventry, UK
5Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
6Department of Respiratory, Scottish Pulmonary Vascular Unit, Glasgow, UK
7Royal Surrey County Hospital NHS Foundation Trust and Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK
8Academic Respiratory Unit, University of Bristol, Bristol, UK
9North Bristol Lung Centre, North Bristol NHS Trust, Bristol, UK
10University Hospital of South Manchester NHS Foundation Trust, Manchester, UK
11Emergency Department, Manchester Royal Infirmary, Central Manchester University Hospitals NHS Foundation Trust, Manchester, Manchester, UK
12University of Plymouth, Plymouth, UK
13Department of Physiotherapy, Guy’s and St Thomas’ NHS Foundation Trust, St Thomas’ Hospital, London, UK
14Aintree University Hospital, Liverpool, UK
15CRAHRC, Imperial College, London, UK
16Queen’s Medical Centre, Nottingham, UK
17Royal College of Physicians, London, UK

**Twitter**

Follow BTS at @BTSrespiratory, Ben Ceagh-Brown at @SPACeRGroup and James Dodd at @theotherdodd

**Acknowledgements**

The authors acknowledge assistance with developing the aims and structure of the guidelines provided by Martin Wildman, Simon Baudouin, Robert Winter, Sara Bolton, Mandy Odell, David Smith and the members of the BTS Standards of Care Committee.

**Collaborators**

BTS Standards of Care Committee members: Colin Gelder, James Dodd and Caroline Patterson.

**Contributors**

ACD chaired the guideline group, and led the drafting and revision of the document. He has final responsibility for the guideline. SB, ME, DK, CG and AG drafted and revised the paper. CC, BC-B, JD, TF, BF, LM, LMCD, RP, CP, MS and LT conducted appraisal of the literature and provided draft sections of the document.

**Representation**

Dr Bob Winter and Sara Bolton represented the Intensive Care Society. Dr Bernard Folei represented the College of Emergency Medicine. Dr Daniel Kennedy represented the Royal College of Anaesthetists and Surgeon Captain Lynn Thomas represented the Royal College of Physicians.

**Competing interests**

ACD declares being paid as a consultant to Smith Medical between 2008 and 2013. ME declares he has received an honorarium, and travel and subsistence expenses for speaking at a meeting in Australia organised by Resmed, a Respiratory Sleep and Ventilation company. He has received a honorarium and travel expenses for speaking at a meeting in London organised by Phillips Respironics, a Respiratory Sleep and Ventilation company. He has received travel expenses for speaking at meetings in India organised by Phillips Respironics, a Respiratory Sleep and Ventilation company. AG declares being paid as a consultant and receiving honoraria and travel expenses for speaking at meetings organised by Armstrong Medical Ltd in the UK, between 2014 and 2015.

**Provenance and peer review**

Not commissioned; internally peer reviewed.

**REFERENCES**


van Oppen JD, Daniel PS, Sovani MP. What is the potential role of transcutaneous carbon dioxide in guiding acute noninvasive ventilation? *Respir Care* 2015;60:484–91.


299 Colebourn CL, Barber V, Young JD. Use of helium-oxygen mixture in adult patients presenting with exacerbations of asthma and chronic obstructive pulmonary disease: a systematic review. Anaesthesia 2007;62: 34–42.

APPENDIX 1 GUIDELINE GROUP MEMBERS
Chair: Craig Davidson
Writing Groups
Acute NIV
Group lead: Mark Elliott,
Members: Colin Church, Tim Felton, Milind Sovani, Lynn McDonnell
Invasive Mechanical Ventilation
Group lead: Daniel Kennedy
Members: Ben Creagh-Brown, Craig Davidson, Alastair Glossop, Leigh Mansfield,
Care Planning
Group lead: Steve Banham
Members: Rob Parker, Craig Davidson, Ben Creagh-Brown, Lynn Thomas, Bernard Foëx
Correction


The British Thoracic Society wishes to clarify reference to the definition of hypercapnia in relation to the BTS/ICS Guidelines for the ventilatory management of acute hypercapnic respiratory failure (2016).

The British Thoracic Society recognises the definition of hypercapnia as a PaCO2 ≥6 kPa as used in the BTS Standards of Care document on non invasive ventilation in acute respiratory failure and BTS Guidelines for Emergency Oxygen Use in Adults.

Previous guidelines recommended that NIV be considered if pH <7.35 and PaCO2 >6 kPa and RR >23 breaths/min. These were predominantly written for patients with exacerbations of Chronic Obstructive Pulmonary Disease. NIV use in the UK has since broadened to treat a number of other diagnoses where the evidence for benefit is less robust and where sometimes there is a mixed metabolic and respiratory acidosis.

In the 2016 BTS/ICS Guidelines for the ventilatory management of acute hypercapnic respiratory failure, the guideline development group considered that in patients with type 2 respiratory failure, a PaCO2 between 6.0 and 6.5 kPa is unlikely to make a large contribution to acidosis. Consensus within the guideline development group and open consultation on the draft guidelines suggested that these patients should receive optimal medical care and controlled flow oxygen while NIV is considered.

The convention and guidance in many centres has evolved to limit the widespread use of NIV in acidosis with a large metabolic contribution and to initiate NIV only in those patients where repeat arterial blood gas measurement confirms a persisting respiratory acidosis pH <7.35 with a higher threshold for PaCO2 >6.5 kPa.

The BTS/ICS Guidelines for the ventilatory management of acute hypercapnic respiratory failure recommendation 25 is amended to:

NIV should be started when a pH <7.35, a PaCO2 of ≥6.5 kPa and RR >23 breaths/mins persists or develops after an hour of optimal medical therapy. (Grade A)

For patients with a PaCO2 between 6.0 and 6.5 kPa NIV should be considered.(Grade D).

The following corrections are also noted:

Page 6 - Definition of AHRF:

“Conventionally a pH <7.35 and a PaCO2 >6.0kPa confirms acute respiratory acidosis and, when persisting after initial medical therapy, have been used as threshold values for considering the use of non-invasive ventilation.”

Page 16:

“In around 20% of AHRF cases secondary to AECOPD, optimised medical therapy, which includes targeting an oxygen saturation to 88–92%, will result in normalisation of arterial pH. Established guidance is to await improvement and initiate NIV if, after 60 min, the following are present: pH <7.35, pCO2 >6.0 kPa and RR >23 breaths/min.148

REFERENCES


